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A B S T R A C T
Background
Primary sclerosing cholangitis is a chronic cholestatic liver disease that is associated with both hepatobiliary and colorectal malignancies,
which can result in liver cirrhosis and its complications. The optimal pharmacological treatment for patients with primary sclerosing
cholangitis remains controversial.
Objectives
To assess the comparative benefits and harms of different pharmacological interventions in people with primary sclerosing cholangitis
by performing a network meta-analysis, and to generate rankings of available pharmacological interventions according to their safety
and efficacy. Given that it was not possible to assess whether potential effect modifiers were similar across comparisons, we did not
perform the network meta-analysis but instead used standard Cochrane methods.
When trials begin to provide an adequate description of potential effect modifiers, we will attempt to conduct network meta-analysis.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index - Expanded, the WHO International Clinical Trials Registry
Platform, and randomised controlled trials registers until February 2017 to identify randomised clinical trials (RCT) on pharmacological
interventions for primary sclerosing cholangitis.
Selection criteria
We included only RCTs, irrespective of language, blinding, or publication status, in which participants were given a diagnosis of
primary sclerosing cholangitis. We excluded trials that included previously liver-transplanted participants. We considered any of various
pharmacological interventions compared with one other or with placebo. We excluded trials that compared different doses of various
pharmacological interventions or that reported different treatment durations, except for ursodeoxycholic acid (UDCA). As UDCA is
the drug most commonly investigated for primary sclerosing cholangitis, we performed a second analysis in which we stratified the
dose of UDCA.
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Data collection and analysis
We calculated the odds ratio and the rate ratio with 95% confidence intervals (CIs) using both fixed-effect and random-effects models
based on available-participant analysis with Review Manager. We assessed risk of bias according to Cochrane, controlled risk of random
errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE.
Main results
We identified 22 RCTs in which 1211 participants were randomised to 13 different interventions. Most were placebo-controlled trials.
Trials had few restrictions apart from an established diagnosis of primary sclerosing cholangitis, evidence of cholestasis, absence of
decompensated liver disease, and absence of malignancy. However, some trials included symptomatic participants only, and others
included both symptomatic and asymptomatic participants. A total of 11 RCTs (706 participants) provided data for one or more
outcomes. The period of follow-up ranged from three months to three years in most trials. Only three trials reported follow-up longer
than three years. Investigators found no evidence of differences in important clinical benefits such as reduction in mortality at maximal
follow-up and improvement in health-related quality of life.
Primary outcomes
Mortality: Effect estimates: colchicine versus placebo: odds ratio 0.44, 95% CI 0.04 to 5.07, participants = 84, one trial; penicillamine
versus placebo: odds ratio 1.18, 95% CI 0.39 to 3.58, participants = 70, one trial; steroids versus placebo: odds ratio 3.00, 95% CI
0.10 to 90.96, participants = 11, one trial; ursodeoxycholic acid versus placebo: odds ratio 1.51, 95% CI 0.63 to 3.63, participants =
348, two trials, I2 = 0%; vancomycin versus placebo: not estimable because no events in either group, participants = 29, one trial.
Serious adverse events (proportion): Effect estimates: infliximab versus placebo: odds ratio not estimable (because of zero events in
both arms), participants = 7, one trial; steroids versus placebo: odds ratio 20.00, 95% CI 0.93 to 429.90, participants = 11, one trial;
vancomycin versus placebo: not estimable because no events in either group, participants = 29, one trial.
Serious adverse events (number): Effect estimates: infliximab versus placebo: rate ratio 0.80, 95% CI 0.02 to 40.44, participants = 7,
one trial; penicillamine versus placebo: rate ratio 13.60, 95% CI 0.78 to 237.83, participants = 70, one trial; steroids versus placebo:
rate ratio 3.32, 95% CI 0.71 to 15.62, participants = 11, one trial.
Adverse events (proportion): Effect estimates: steroids versus placebo: odds ratio 20.00, 95% CI 0.93 to 429.90, participants = 11,
one trial; ursodeoxycholic acid versus placebo: odds ratio 1.22, 95% CI 0.68 to 2.17, participants = 198, one trial; vancomycin versus
placebo: not estimable because no events in either group, participants = 29, one trial.
Adverse events (number): Effect estimates: cyclosporin versus placebo: rate ratio 2.64, 95% CI 0.99 to 7.03, participants = 26, one trial;
steroids versus placebo: rate ratio 3.32, 95% CI 0.71 to 15.62, participants = 11, one trial; ursodeoxycholic acid plus metronidazole
versus ursodeoxycholic acid: rate ratio 2.36, 95% CI 0.98 to 5.71, participants = 71, one trial.
Health-related quality of life: ursodeoxycholic acid versus placebo: mean difference 1.30, 95% CI -5.61 to 8.21, participants = 198,
one trial (Short Form (SF)-36 General Health Scale).
Secondary outcomes
Studies provided no evidence of differences in clinical benefits such as a reduction in the requirement for liver transplantation or a
reduction in the incidence proportion of cholangiocarcinoma. One small trial (29 participants) comparing vancomycin versus placebo
reported no malignancies, no liver decompensation, and no liver transplantation in either group after a very short follow-up period
of 12 weeks after treatment. None of the remaining trials clearly reported other clinical benefits such as decreased development of all
malignancies, colorectal cancer, liver decompensation, time to liver decompensation, time to liver transplantation, or requirement for
cholecystectomy to allow comparisons between different interventions.
Source of funding: Fifteen trials reported the source of funding; three were funded by parties without vested interest in results of the
trial, and 12 were funded in part or in full by drug companies.
Authors’ conclusions
Evidence is currently insufficient to show differences in effectiveness measures such as mortality, health-related quality of life, cirrhosis,
or liver transplantation between any active pharmacological intervention and no intervention. However, trials were at high risk of bias
and included small numbers of participants, had short follow-up periods, and reported few clinical outcomes. An urgent need exists
to identify an effective medical treatment for primary sclerosing cholangitis through well-designed RCTs with adequate follow-up that
aim to identify differences in outcomes important to people with primary sclerosing cholangitis.
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P L A I N L A N G U A G E S U M M A R Y
Medical treatment for people with primary sclerosing cholangitis
Background
Primary sclerosing cholangitis is a disease that affects the bile ducts. Bile ducts are tubes that transport the bile produced by liver cells.
Primary sclerosing cholangitis is a relatively uncommon disease, with 1 in 10,000 people affected. It is more common among men,
and most people receive the diagnosis at between 30 and 50 years of age. Primary sclerosing cholangitis can lead to liver damage,
liver failure, and bile duct cancer, and it decreases a person’s longevity. Various medical treatments for primary sclerosing cholangitis
have been tested. The best way to treat patients with primary sclerosing cholangitis remains unclear. We sought to resolve this issue
by searching for studies conducted to explore this topic. We included all randomised clinical trials whose results were reported until
February 2017. We included only trials in which participants had not undergone liver transplantation before participating in the trial.
Apart from using standard Cochrane methods, which allow comparison of only two treatments at a time (direct comparison), we
planned to use an advanced method (network meta-analysis) that would allow comparison of many different individual treatments as
reported by research trials. However, because of the nature of the available information, we could not determine whether results of the
network meta-analysis were reliable. So, we used standard Cochrane methods instead.
Study characteristics
We identified 22 randomised clinical trials with a total of 2211 participants that met our inclusion criteria. Participants in these trials
were randomised to 13 different treatments. In most trials, placebo (dummy treatment) was provided as one of the treatments. Trials
applied few restrictions apart from confirmation of primary sclerosing cholangitis, evidence of bile stagnation, which is an early marker
of primary sclerosing cholangitis, absence of liver failure, and absence of cancer. However, only 11 trials (706 participants) provided
the information that we sought. The remaining trials, which were conducted in people with primary sclerosing cholangitis, compared
different treatments but did not report important information on deaths, complications, health-related quality of life, liver failure, liver
transplantation, or cancer. Participants in most of these trials were followed-up only for three months to three years. Only three trials
followed-up trial participants for longer than three years.
Source of funding: Fifteen trials reported their source of funding; three of these were funded by parties without vested interest in results
of the trial, and 12 were funded in part or in full by drug companies.
Key results
Differences in important clinical benefits such as reduction in mortality (deaths) at maximal follow-up, improvement in health-
related quality of life, reduction in the requirement for liver transplantation, or reduction in development of cholangiocarcinoma were
imprecise in all comparisons. Other important clinical benefits such as incidence proportion of all malignancies, colorectal cancer,
liver decompensation, time to liver decompensation, and time to liver transplantation and requirement for cholecystectomy were not
reported in any trial in a format that could be analysed to allow comparison between different treatments. No evidence currently
suggests that any medical treatment for primary sclerosing cholangitis is effective. An urgent need exists to identify an effective medical
treatment for patients with primary sclerosing cholangitis by performing additional well-designed randomised clinical trials.
Quality of evidence
The overall quality of evidence was very low, and all trials were judged to be at high risk of bias, which means that wrong conclusions
may overestimate benefits or underestimate harms of one treatment or another because of the way the trials were conducted.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ursodeoxycholic acid versus placebo for primary sclerosing cholangitis
Patient or population: people with primary sclerosing cholangit is
Settings: secondary or tert iary care
Intervention: ursodeoxycholic acid
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo Ursodeoxycholic acid
Mortality
Follow-up: 60 months
72 per 1000 105 per 1000
(47 to 220)
OR 1.51
(0.63 to 3.63)
348
(2 trials)
⊕©©©
very low1,2,3
Serious adverse events No trials reported the number of part icipants with serious adverse events or numbers of serious adverse events
Proportion of people with
adverse events
Follow-up: 60 months
337 per 1000 358 per 1000
(237 to 498)
OR 1.22
(0.68 to 2.17)
198
(1 trial)
⊕©©©
very low1,2,3
Number of adverse events No trials reported the number of adverse events.
Health- related quality of
life
Follow-up: 5 years
Scale: SF-36 General Health
Scale (Lim its: 0 to 100;
higher = better)
Mean in the placebo group
was 61.10.
Mean in the ursodeoxy-
cholic acid group was 1.30
higher (5.61 lower or 8.21
higher)
- 198
(1 trial)
⊕©©©
very low1,2,3
Liver transplantation
Follow-up: 60 months
123 per 1000 120 per 1000
(68 to 202)
OR 0.97
(0.52 to 1.81)
348
(2 trials)
⊕©©©
very low1,2,3,4
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Any malignancy No trials reported this outcome.
Cholangiocarcinoma
Follow-up: 60 months
43 per 1000 57 per 1000
(21 to 142)
OR 1.34
(0.48 to 3.68)
348
(2 trials)
⊕©©©
very low1,2,3
Colorectal cancer No trials reported this outcome.
Cholecystectomy No trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion. The corresponding risk (and its 95% conf idence interval) is based on assumed risk in the comparison
group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level for risk of bias: the trial(s) were at high risk of bias.
2 Downgraded one level for imprecision: the sample size was small.
3 Downgraded one level for imprecision: the conf idence intervals were wide and overlapped a clinically signif icant reduct ion
or increase (25% reduct ion or increase) and no ef fect.
4 Downgraded two levels for inconsistency: I2 was high and overlap of conf idence intervals was poor.
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B A C K G R O U N D
Description of the condition
Primary sclerosing cholangitis is a chronic inflammatory disease of
the liver involving intrahepatic or extrahepatic bile ducts, or both,
that is characterised by fibrosis with bile duct strictures, stasis of
bile (cholestasis), liver fibrosis, and liver cirrhosis (NCBI 2014).
Global variation has been noted in the incidence and prevalence
of primary sclerosing cholangitis, with annual incidence varying
from 0.07 to 1.3 per 100,000 people, prevalence ranging from
0.2 to 13.6 per 100,000 people, and a trend showing increasing
incidence (Boonstra 2012). Primary sclerosing cholangitis is more
common in men (Boonstra 2012). Most people with this dis-
ease receive the diagnosis when they are between 30 and 50 years
of age (Talwalkar 2001). A significant association has been ob-
served between inflammatory bowel disease (ulcerative colitis and
Crohn’s disease that predominantly affects the colon) and primary
sclerosing cholangitis, with about 20% to 75% of people with
primary sclerosing cholangitis having inflammatory bowel disease
(O’Mahony 2006; Chapman 2008; Boonstra 2012). The cause
of primary sclerosing cholangitis is unclear. Although genetic and
environmental factors are recognised, themain hypotheses regard-
ing cause are that primary sclerosing cholangitis is an autoimmune
disorder (i.e. immune system incorrectly recognises bile ducts as
foreign material and attacks them), and that it is an immune-me-
diated inflammatory disease (i.e. some triggering factor incites ac-
tivation of the immune mechanism, leading to damage to the bile
ducts) (O’Mahony 2006). People with certain human leukocyte
antigen (HLA) typing are more likely to develop primary scle-
rosing cholangitis, although genes outside the HLA also play a
role in its development (O’Mahony 2006; Chapman 2008; Liu
2013). The role of bacteria and viruses in the development of pri-
mary sclerosing cholangitis in susceptible people remains unclear
(O’Mahony 2006; Chapman 2008).
Diagnosis of primary sclerosing cholangitis is based on the pres-
ence of biochemical features of cholestasis (i.e. elevated alkaline
phosphatase or serumbilirubin) or elevation of both alkaline phos-
phatase and serum bilirubin with characteristic bile duct changes
(i.e. multiple short segment strictures and segmental dilatation)
on cholangiography, when other causes of biliary stricture and
cholestasis have been excluded (EASL 2009; Chapman 2010).
Causes of biliary stricture that need to be excluded include malig-
nancy, iatrogenic causes (i.e. bile duct injury during cholecystec-
tomy (Stewart 2014)), ischaemia (i.e. injury during cholecystec-
tomy (Stewart 2014) or following liver transplantation (Jay 2011)),
immunoglobulin (Ig)G4-related cholangitis, recurrent pyogenic
cholangitis, and recurrent pancreatitis (Chapman 2010). Biliary
strictures not caused by primary sclerosing cholangitis are called
secondary sclerosing cholangitis. The distinction between primary
and secondary sclerosing cholangitis may be difficult, particu-
larly for people who have undergone previous surgery on the liver
and biliary tract. Inflammatory bowel disease in people with bile
duct stricture favours a diagnosis of primary sclerosing cholangi-
tis (Chapman 2010). It should be noted that bilirubin or alka-
line phosphatase may be normal in people with primary sclerosing
cholangitis (Chapman 2010). Currently, antibody tests including
perinuclear antineutrophil cytoplasmic antibody (pANCA) have
no role in the diagnosis of primary sclerosing cholangitis because
these antibodies are non-specific (Chapman 2010). Although var-
ious prognostic models have been developed for people with pri-
mary sclerosing cholangitis, use of these models has not been rec-
ommended because experts have not reached consensus on their
usefulness (Chapman 2010). Approximately 50% of people die or
require liver transplantation after about 20 years (Boonstra 2013).
Variant forms of primary sclerosing cholangitis include small duct
primary sclerosing cholangitis (wherein bile duct dilatation is not
noted on endoscopic retrograde cholangiopancreatography but
liver biopsy reveals the diagnosis of primary sclerosing cholangi-
tis) and autoimmune hepatitis (a primary sclerosing cholangitis
variant syndrome in which cholangiographic features suggest pri-
mary sclerosing cholangitis but biochemical and histological fea-
tures suggest autoimmune hepatitis) (Yimam 2014).
Description of the intervention
Various pharmacological interventions have been tried to treat
people with primary sclerosing cholangitis. These include the bile
acids ursodeoxycholic acid (UDCA) and tauro-ursodeoxycholic
acid (TUDCA) (Perez 2009; Poropat 2011), immunosuppres-
sants or immunomodulators such as glucocorticosteroids (Giljaca
2010), methotrexate (Novak 2008), mycophenolate mofetil (
Talwalkar 2005), etanercept (Epstein 2004), probiotics (Vleggaar
2008), and copper chelating agents (agents that remove copper)
such as D-penicillamine (Klingenberg 2006). Endoscopic inter-
ventions such as balloon dilatation of localised strictures, endo-
scopic stenting to relieve cholestasis (Koro 2013), surgical inter-
ventions such as extrahepatic biliary resection for relief of symp-
toms in people with primary sclerosing cholangitis without ad-
vanced cirrhosis (Pawlik 2008), liver resection for hilar cholangio-
carcinoma associated with primary sclerosing cholangitis (Valero
2012), and liver transplantation in cases of cirrhosis (Klose 2014)
or cholangiocarcinoma (Gores 2013) are the other interventions
used to treat patients with primary sclerosing cholangitis.
How the intervention might work
Given the presumed mechanism of the disease, which is centred
around the bile ducts, and knowledge of when immune mecha-
nisms are implicated in development and/or progression of the dis-
ease, many interventions evaluated for primary sclerosing cholan-
gitis have been immunomodulatory; others have been known to
modify the enterohepatic circulation of bile acids.
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Certain bile acids are protective of, and others are harmful to, hep-
atocytes (liver cells), cholangiocytes (cells that line the bile duct),
and other gastrointestinal cells lining the oesophagus and stomach
(Perez 2009). Bile acids such as UDCA and TUDCA may pro-
tect cholangiocytes from damage caused by hydrophobic bile acids
by decreasing oxidative stress (through a direct antioxidant effect
or an increase in antioxidant defences) (Paumgartner 2002; Perez
2009). Bile acids also stimulate choleresis (secretion of bile acids
from liver cells (hepatocytes)), thereby decreasing cholestasis and
resulting damage to cells and inhibiting apoptosis (programmed
cell death) (Paumgartner 2002; Perez 2009). Primary sclerosing
cholangitis is considered an autoimmune disorder or an immune-
mediated inflammatory disease (O’Mahony 2006); therefore, al-
tering immunity and the inflammatory response with glucocor-
ticoids and other immunosuppressants may decrease damage re-
sulting from the inflammatory response.
Alternative treatment strategies that have been explored in pri-
mary sclerosing cholangitis include modifying the metabolism of
copper. It is recognised that people with sclerosing cholangitis ex-
perience an accumulation of copper in the liver (Gross 1985). D-
pencillamine might remove the excess copper, thereby protecting
hepatocytes from damage caused by copper accumulation. Endo-
scopic interventions and extrahepatic biliary resections work by
relieving cholestasis when a dominant bile duct stricture is present.
In addition, extrahepatic biliary resections result in excision of dis-
eased tissue. Liver resection for hilar cholangiocarcinoma results
in excision of cancers that develop in people with primary scle-
rosing cholangitis. Liver transplantation is aimed at replacing the
liver of the person with advanced liver cirrhosis with a functioning
liver.We have included only pharmacological interventions in this
Cochrane review (i.e. we have excluded endoscopic and surgical
interventions).
Why it is important to do this review
The optimal pharmacological intervention for primary sclerosing
cholangitis is not known. Currently, no pharmacological interven-
tion is recommended for the treatment of individuals with primary
sclerosing cholangitis, except for the variant form, namely, autoim-
mune hepatitis-primary sclerosing cholangitis variant syndrome,
for which glucocorticoid treatment is recommended (Chapman
2010). Through this systematic review and attempted network
meta-analysis, we intend to provide evidence of highest quality
showing the role of different interventions used to treat people
with primary sclerosing cholangitis.
O B J E C T I V E S
To assess the comparative benefits and harms of different pharma-
cological interventions in people with primary sclerosing cholan-
gitis by performing a networkmeta-analysis, and to generate rank-
ings of available pharmacological interventions according to their
safety and efficacy. Given that it was not possible to assess whether
potential effect modifiers were similar across comparisons, we did
not perform the network meta-analysis but instead used standard
Cochrane methods to assess the benefits and harms of different
interventions.
When trials begin to provide an adequate description of potential
effect modifiers, we will attempt to conduct network meta-analy-
sis to generate rankings of available pharmacological interventions
according to their safety and efficacy. For this reason, we have re-
tained (in Appendix 1) the plan to perform network meta-analy-
sis. Once sufficient data are available for network meta-analysis,
we will move Appendix 1 back into the Methods section of this
review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this systematic
review, irrespective of language, publication status, or date of pub-
lication. We excluded studies of other design because of the risk
of bias associated with such studies. We are aware that such exclu-
sions make us focus much more on potential benefits while not
fully assessing risks of serious adverse events and risks of adverse
events.
Types of participants
We included randomised clinical trials with participants with pri-
mary sclerosing cholangitis, irrespective of method of diagnosis,
presence of symptoms, or whether primary sclerosing cholangitis
is associated with inflammatory bowel disease. We excluded ran-
domised clinical trials in which participants had previously under-
gone liver transplantation.
Types of interventions
We included studies comparing any of the following pharmaco-
logical interventions used alone or in combination for treatment of
primary sclerosing cholangitis versus each other or versus placebo
or no intervention.
We considered the following interventions.
1. Ursodeoxycholic acid (UDCA).
2. Tauro-ursodeoxycholic acid (TUDCA).
3. Glucocorticosteroids.
4. Methotrexate.
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5. Mycophenolate mofetil.
6. Etanercept.
7. Probiotics.
8. D-penicillamine.
9. Colchicine.
10. Infliximab.
11. Vancomycin.
12. Metronidazole.
The above list is not exhaustive. If we identified pharmacological
interventions of which we were not aware, we considered them as
eligible and included them in the review if they are used primarily
for treatment of individuals with primary sclerosing cholangitis.
Types of outcome measures
We assessed the benefits and harms of available pharmacological
interventions used to treat people with primary sclerosing cholan-
gitis in terms of the following outcomes.
Primary outcomes
1. Mortality.
i) Short-term mortality (up to one year).
ii) Medium-term mortality (one to five years).
iii) Mortality at maximum follow-up.
2. Adverse events. We defined an adverse event as any
untoward medical occurrence not necessarily having a causal
relationship with treatment but resulting in a dose reduction or
discontinuation of treatment (ICH-GCP 1997) (at any time
after commencement of treatment). We defined a serious adverse
event as any event that would increase mortality; is life-
threatening; required inpatient hospitalisation; resulted in
persistent or significant disability; or was a congenital anomaly/
birth defect; or any important medical event that might have
jeopardised the person or required intervention to prevent it. We
used the definitions used by trial authors for adverse events and
serious adverse events.
i) Proportion of participants with serious adverse events.
ii) Number of serious adverse events.
iii) Proportion of participants with any type of adverse
event.
iv) Numbers of adverse events of any type.
3. Quality of life as defined by the authors of included trials
using a validated scale such as the EuroQol Group Quality of
Life Questionnaire (EQ-5D) or the Short Form (SF)-36 General
Health Scale (EuroQol 2014; Ware 2014).
i) Short-term (up to one year).
ii) Medium-term (one to five years).
iii) Long-term (beyond five years).
Secondary outcomes
1. Liver transplantation.
i) Proportion of participants with liver transplantation.
ii) Time to liver transplantation.
2. Decompensated liver disease (long-term).
i) Proportion of participants with decompensated liver
disease.
ii) Time to liver decompensation.
3. Any malignancy (long-term), in particular,
cholangiocarcinoma and colorectal cancer.
4. Cholecystectomy (long-term).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, and Science Citation Index
- Expanded (Royle 2003) from inception to 22 February 2017
for randomised clinical trials comparing two or more of the above
interventions. We searched for all possible comparisons including
the interventions of interest. To identify additional ongoing or
completed trials, we searched the World Health Organization In-
ternational Clinical Trials Registry Platform search portal, which
includes trials from various trial registers, including International
Standard Randomized Controlled Trials Number (ISRCTN) and
ClinicalTrials.gov. Search strategies are available in Appendix 2.
Searching other resources
We searched the references of identified trials and existing
Cochrane reviews on primary sclerosing cholangitis to identify ad-
ditional trials for inclusion.
Data collection and analysis
Selection of studies
Three review authors (FS, KG, and CT) independently identified
trials for inclusion by screening titles and abstracts yielded by the
search. We sought full-text articles for all references that at least
one of the review authors had identified for potential inclusion.
We selected trials for inclusion on the basis of review of full-text
articles. We listed excluded full-text references along with reasons
for their exclusion in the Characteristics of excluded studies ta-
ble. We planned to list for further follow-up any ongoing trials
identified primarily via search of clinical trial registers.We resolved
discrepancies through discussion.
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Data extraction and management
Three review authors (FS, KG, and CT) independently extracted
the following data.
1. Outcome data (for each outcome and for each treatment
arm when applicable).
i) Number of participants randomised.
ii) Number of participants included for analysis.
iii) Number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and number of
participants with events and average follow-up period for time-
to-event outcomes.
iv) Definition of outcomes or scale used, if appropriate.
2. Data on potential effect modifiers.
i) Participant characteristics such as age, sex,
comorbidity, presence of symptoms, and number and proportion
of participants with inflammatory bowel disease.
ii) Details of intervention and control (including dose,
frequency, and duration) such as treatment for inflammatory
bowel disease.
iii) Risk of bias (assessment of risk of bias in included
studies).
3. Other data.
i) Year and language of publication,
ii) Country in which participants were recruited.
iii) Year(s) in which trial was conducted.
iv) Inclusion and exclusion criteria.
v) Follow-up time points of the outcome.
We planned to obtain data separately for symptomatic participants
and asymptomatic participants, if available from the report. We
also planned to obtain data separately for participants with in-
flammatory bowel disease and those without inflammatory bowel
disease, if available. We sought unclear or missing information
by contacting trial authors. If we had any doubt whether trials
shared the same participants - completely or partially (by identi-
fying common trial authors and centres) - we made attempts to
contact trial authors to clarify whether the trial report was dupli-
cated. We resolved differences in opinion through discussion.
Assessment of risk of bias in included studies
We followed guidance as provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) and described
in the Cochrane Hepato-Biliary Group Module (Gluud 2013) to
assess risk of bias in included studies. Specifically, we assessed risk of
bias in included trials for the following domains using themethods
below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
1. Low risk of bias: trial authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if an independent person
not otherwise involved in the study performed them.
2. Unclear risk of bias: trial authors did not specify the
method of sequence generation.
3. High risk of bias: the sequence generation method was not
random. We planned to include such studies only for assessment
of harms.
Allocation concealment
1. Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
2. Unclear risk of bias: the trial authors did not describe the
method used to conceal the allocation so the intervention
allocations may have been foreseen before, or during, enrolment.
3. High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We will
include such studies only for assessment of harms.
Blinding of participants and personnel
1. Low risk of bias: any of the following: no blinding or
incomplete blinding, but review authors judge that the outcome
is not likely to be influenced by lack of blinding; or blinding of
participants and key study personnel ensured, and it is unlikely
that blinding could have been broken.
2. Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
3. High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but it is likely that blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
1. Low risk of bias: any of the following: no blinding of
outcome assessment, but review authors judge that outcome
measurement is not likely to be influenced by lack of blinding; or
blinding of outcome assessment ensured, and it is unlikely that
blinding could have been broken.
2. Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
3. High risk of bias: any of the following: no blinding of
outcome assessment, and outcome measurement is likely to be
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influenced by lack of blinding; or blinding of outcome
assessment, but it is likely that blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
Incomplete outcome data
1. Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
2. Unclear risk of bias: there was insufficient to assess whether
missing data in combination with the method used to handle
missing data was likely to induce bias on results.
3. High risk of bias: results were likely to be biased owing to
missing data.
Selective outcome reporting
1. Low risk of bias: the trial reported the following predefined
outcomes: mortality, or decompensated liver disease, or
requirement for transplantation along with treatment-related
adverse events. If the original trial protocol was available,
outcomes should be those called for in that protocol. If the trial
protocol was obtained from a trial registry (e.g.
www.clinicaltrials.gov), outcomes sought should be those
enumerated in the original protocol if the trial protocol was
registered before or at the time the trial was begun. If the trial
protocol was registered after the trial was begun, we will not
consider those outcomes to be reliable.
2. Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded.
3. High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
although data on these outcomes should have been available and
even recorded.
For-profit bias
1. Low risk of bias: the trial appeared to be free of industry
sponsorship or another type of for-profit support that could
manipulate trial design, conductance, or results.
2. Unclear risk of bias: the trial may or may not be free of for-
profit bias, as no information on clinical trial support or
sponsorship was provided.
3. High risk of bias: the trial was sponsored by industry or
received another type of for-profit support.
Other bias
1. Low risk of bias: the trial appeared to be free of other
components (e.g. inappropriate control or dose or
administration of control, baseline differences, early stopping)
that could put it at risk of bias.
2. Unclear risk of bias: the trial may or may not be free of
other components that could put it at risk of bias.
3. High risk of bias: other factors in the trial could put it at
risk of bias (e.g. inappropriate control or dose or administration
of control, baseline differences, early stopping).
We considered a trial to be at low risk of bias if we assessed it to be
at low risk of bias across all domains. Otherwise, we considered a
trial to be at high risk of bias regarding one or more domains.
Measures of treatment effect
For dichotomous variables (e.g. short-term and medium-term
mortality or liver transplantation, proportion of participants with
adverse events, decompensated liver disease, cirrhosis, hepatocel-
lular carcinoma), we calculated odds ratios with 95% confidence
intervals (CIs). For continuous variables (e.g. quality of life re-
ported on the same scale), we planned to calculate mean differ-
ences with 95% CIs. We planned to use standardised mean dif-
ference values with 95% CIs for quality of life, if included trials
used different scales. For count outcomes (e.g. numbers of adverse
events), we calculated rate ratios with 95% CIs. For time-to-event
data (e.g. mortality at maximal follow-up or requirement for liver
transplantation, time to liver decompensation, time to cirrhosis),
we planned to use hazard ratios with 95% CIs. We also calculated
Trial Sequential Analysis-adjusted CIs to control random errors
(Thorlund 2011).
Unit of analysis issues
The unit of analysis was people with primary sclerosing cholangitis
according to the intervention group to which they were randomly
assigned.
Cluster-randomised clinical trials
As expected, we did not find cluster-randomised clinical trials.
However, if we had found them, we planned to include them,
provided that the effect estimate adjusted for cluster correlation
was available.
Cross-over randomised clinical trials
We found one cross-over randomised clinical trial (Rasmussen
1998). We planned to include outcomes after the period of first
treatment because primary sclerosing cholangitis is a chronic dis-
ease and treatments could potentially have a residual effect.
Trials with multiple treatment groups
We collected data for all trial intervention groups that met the
inclusion criteria.
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Dealing with missing data
We performed an intention-to-treat analysis (Newell 1992) when
possible. Otherwise, we used data that were available to us (e.g. a
trial may have reported only per-protocol analysis results). Given
that such ’per-protocol’ analyses may be biased, we planned to
conduct best/worst-case scenario (good outcome in intervention
group and bad outcome in control group) and worst/best-case
scenario (bad outcome in intervention group and good outcome
in control group) analyses as sensitivity analyses when possible.
For continuous outcomes, we used analysis of available cases. We
planned to impute the standard deviation from P values according
to guidance given in Higgins 2011. If data were likely to be nor-
mally distributed, we planned to use the median for meta-analysis
when the mean was not available. When it was impossible to cal-
culate the standard deviation from the P value or the confidence
intervals, we planned to impute the standard deviation using the
largest standard deviation in other trials for that outcome. This
form of imputation may decrease the weight of the study for cal-
culation of mean differences and may bias the effect estimate to
no effect for calculation of standardised mean differences (Higgins
2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We
planned to assess the presence of clinical heterogeneity by compar-
ing effect estimates in the presence or absence of symptoms, the
presence or absence of inflammatory bowel disease along with pri-
mary sclerosing cholangitis, and doses of pharmacological inter-
ventions. Different study designs and risk of bias may contribute
to methodological heterogeneity. We used the I2 test and the Chi
2 test and overlapping of CIs to assess for heterogeneity.
Assessment of reporting biases
We planned to use visual asymmetry on a funnel plot to explore
reporting bias when we could include at least 10 trials for di-
rect comparison (Egger 1997; Macaskill 2001). In the presence
of heterogeneity that could be explained by subgroup analysis, we
planned to prepare the funnel plot for each subgroup with an ad-
equate number of trials. We planned to use the linear regression
approach described by Egger 1997 to determine funnel plot asym-
metry. None of the comparisons involved 10 or more trials, so we
did not explore reporting biases.
We considered selective reporting as evidence of reporting bias.
Data synthesis
We performed meta-analyses according to Cochrane recommen-
dations (Higgins 2011), using the software package Review
Manager 5 (RevMan 2014). We used a random-effects model
(DerSimonian 1986) and a fixed-effect model (Demets 1987).
Whenwe found discrepancy between the twomodels, we reported
both results; otherwise, we reported only results from the fixed-
effect model.
Calculation of required information size and Trial Sequential
Analysis
For calculation of required information size, see Appendix 3. We
performed Trial Sequential Analysis to control risks of random
error (Wetterslev 2008; Thorlund 2011; TSA 2011) when we
included at least two trials in the meta-analysis. We used an alpha
error as per guidance provided by Jakobsen 2014, power of 90%
(beta error of 10%), relative risk reduction of 20%, control group
proportions observed in trials, and diversity as observed in the
meta-analysis.
Subgroup analysis and investigation of heterogeneity
We planned to assess differences in effect estimates between the
following subgroups.
1. Trials with low risk of bias compared to trials with high risk
of bias.
2. Participants with symptomatic compared to participants
with asymptomatic primary sclerosing cholangitis.
3. Participants with present inflammatory bowel disease
compared to participants with absent inflammatory bowel
disease.
4. Different doses of pharmacological interventions. For
example, doses of ursodeoxycholic acid used in randomised
clinical trials include 13 mg to 15 mg/kg/d for low-dose (Lindor
1997), 17 mg to 23 mg/kg/d for moderate-dose (Olsson 2005),
and 28 mg to 30 mg/kg/d for high-dose ursodeoxycholic acid
(Lindor 2009).
Weplanned touse theChi2 test for subgroupdifferences to identify
subgroup differences.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned to
re-analyse these results using best/worst-case scenario and worst/
best-case scenario analyses as sensitivity analyses when possible.
We did not do this because we found insufficient information.
Presentation of results and GRADE assessments
We reported all outcomes in a ’Summary of findings’ table format,
downgrading the quality of evidence for risk of bias, inconsistency,
indirectness, imprecision, and publication bias using GRADE (
Guyatt 2011) for comparisons with at least two trials.
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Description of studies
Results of the search
We identified 3320 references through electronic searches of
CENTRAL (N = 277), MEDLINE (N = 1612), Embase (N
= 458), Science Citation Index - Expanded (N = 908), the
World Health Organization International Clinical Trials Reg-
istry Platform (N = 37) and randomised controlled trials reg-
isters (N = 28). After we removed 689 duplicates, 2631 refer-
ences remained. We then excluded 2528 clearly irrelevant ref-
erences by screening titles and reading abstracts. We retrieved
103 references for further assessment. We identified no refer-
ences by scanning the reference lists of identified randomised tri-
als. We excluded 48 references (37 studies) for the reasons listed
in the Characteristics of excluded studies table. Three trials are
awaiting classification (Anonymous 2006; ISRCTN16531030;
NCT00059202). Ten are ongoing trials without interim data
(EUCTR2012-004170-26-IT; EUCTR2015-003310-24-SE;
EUCTR2015-003392-30-GB;NCT01672853;NCT01688024;
NCT01755507; NCT02177136; NCT02704364;
NCT02943460; NCT03035058). In total, 22 trials (42 refer-
ences) met the inclusion criteria of this review (Allison 1986;
LaRusso 1988; Stiehl 1989; Beuers 1992; Lo 1992; Sandborn
1993; Knox 1994; Olsson 1995; Bansi 1996; De Maria 1996;
Lindor 1997; Rasmussen 1998; Mitchell 2001; Farkkila 2004;
Sterling 2004; Olsson 2005; Cullen 2008; Hommes 2008; Lindor
2009; Tabibian 2013; Rahimpour 2016; Trauner 2016). The ref-
erence flow is summarised in the study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We have summarised the interventions used in the 22 ran-
domised clinical trials in the Characteristics of included studies
tables. All trials assessed potential pharmacological interventions,
given alone or in combination, for primary sclerosing cholan-
gitis. Twenty-one trials were parallel randomised clinical trials
(Allison 1986; LaRusso 1988; Stiehl 1989; Beuers 1992; Lo
1992; Sandborn 1993; Knox 1994; Olsson 1995; Bansi 1996;
De Maria 1996; Lindor 1997; Mitchell 2001; Farkkila 2004;
Sterling 2004; Olsson 2005; Cullen 2008; Hommes 2008; Lindor
2009; Tabibian 2013; Rahimpour 2016; Trauner 2016), and one
was a cross-over randomised clinical trial (Rasmussen 1998). Of
the 21 parallel randomised clinical trials, 17 were two-arm trials
(Allison 1986; LaRusso 1988; Stiehl 1989; Beuers 1992; Lo 1992;
Sandborn 1993; Knox 1994; Olsson 1995; Bansi 1996; Lindor
1997; Mitchell 2001; Farkkila 2004; Sterling 2004; Olsson 2005;
Hommes 2008; Lindor 2009; Rahimpour 2016), two were three-
arm trials (De Maria 1996; Cullen 2008), and two were four-arm
trials (Tabibian 2013; Trauner 2016). The cross-over randomised
clinical trial was a two-armed trial (Rasmussen 1998).
A total of 1211 participants were randomised to 13 different in-
terventions in the 22 trials. Comparisons included the following.
Colchicine versus placebo
Olsson 1995: colchicine (44 participants) versus placebo (44 par-
ticipants); follow-up 36 months.
Cyclosporin versus placebo
Sandborn 1993: cyclosporin (16 participants) versus placebo (16
participants); follow-up 35 months.
Infliximab versus placebo
Hommes 2008: infliximab (4 participants) versus placebo (4 par-
ticipants); follow-up 13 months.
Methotrexate versus placebo
Knox 1994: methotrexate (11 participants) versus placebo (11
participants); follow-up 48 months.
Rasmussen 1998: methotrexate (five participants) versus placebo
(eight participants); follow-up 24 months (Note: This was a cross-
over randomised clinical trial, and participants crossed over to the
opposite arm at one year).
NorUrsodeoxycholic acid versus placebo
Trauner 2016: NorUrsodeoxycholic acid (randomised to 500 mg/
d or 1000 mg/d or 1500 mg/d) (participants: not stated) versus
placebo (participants: not stated); follow-up one month.
Penicillamine versus placebo
LaRusso 1988: penicillamine (39 participants) versus placebo (39
participants); follow-up 36 months.
Steroids versus placebo
Allison 1986: steroids (six participants) versus placebo (six partic-
ipants); follow-up three months.
UDCA (high) versus placebo
Lindor 2009: UDCA (high) (76 participants) versus placebo (76
participants); follow-up 60 months (in some participants).
UDCA (moderate) versus placebo
Bansi 1996: UDCA (moderate) (11 participants) versus placebo
(11 participants); follow-up 12 months.
Mitchell 2001: UDCA (moderate) (13 participants) versus
placebo (13 participants); follow-up 24 months.
Olsson 2005: UDCA (moderate) (97 participants) versus placebo
(97 participants); follow-up 60 months.
UDCA (low) versus placebo
Beuers 1992: UDCA (low) (six participants) versus placebo (six
participants); follow-up 12 months.
Lindor 1997: UDCA (low) (51 participants) versus placebo (51
participants); follow-up 27 months.
Lo 1992: UDCA (low) (seven participants) versus placebo (seven
participants); follow-up 24 months.
Stiehl 1989: UDCA (low) (six participants) versus placebo (six
participants); follow-up not stated clearly.
UDCA (low) versus UDCA (moderate) versus UDCA (high)
Cullen 2008: UDCA (low) (11 participants) versus UDCA (mod-
erate) (11 participants) versus UDCA (high) (nine participants);
follow-up 24 months.
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UDCA (low) versus colchicine versus placebo
De Maria 1996: UDCA (low) (20 participants) versus colchicine
(20 participants) versus placebo (20 participants); follow-up 24
months.
UDCA (low) plus metronidazole versus UDCA (low)
Farkkila 2004: UDCA (low) plus metronidazole (37 participants)
versus UDCA (low) (37 participants); follow-up 36 months.
UDCA (low) plus mycophenolate versus UDCA (low)
Sterling 2004: UDCA (low) plus mycophenolate (six participants)
versus UDCA (low) (six participants); follow-up 24 months.
Vancomycin versus metronidazole
Tabibian 2013: vancomycin (randomised to 125 mg or 250 mg
thrice daily) (16 participants) versus metronidazole (randomised
to 250 mg or 500 mg thrice daily) (16 participants); follow-up 24
months.
Vancomycin versus placebo
Rahimpour 2016: vancomycin (18 participants) versus placebo
(11 participants); follow-up three months.
Themean ormedian age of participants ranged from31 years to 53
years in the 19 trials that reported this information (Allison 1986;
LaRusso 1988; Beuers 1992; Lo 1992; Sandborn 1993; Knox
1994; Olsson 1995; Bansi 1996; De Maria 1996; Lindor 1997;
Mitchell 2001; Farkkila 2004; Sterling 2004; Olsson 2005; Cullen
2008; Hommes 2008; Lindor 2009; Tabibian 2013; Rahimpour
2016). The proportion of females ranged from 21.4% to 62.5%
in the 19 trials that reported this information (Allison 1986;
LaRusso 1988; Beuers 1992; Lo 1992; Sandborn 1993; Knox
1994; Olsson 1995; Bansi 1996; De Maria 1996; Lindor 1997;
Mitchell 2001; Farkkila 2004; Sterling 2004; Olsson 2005; Cullen
2008; Hommes 2008; Lindor 2009; Tabibian 2013; Rahimpour
2016). The follow-up period inmost trials ranged fromonemonth
to five years, and only three trials had a follow-up period longer
than three years (Knox 1994; Olsson 2005; Lindor 2009). Of
these, one trial reported follow-up of five years in selected par-
ticipants only, and the period of follow-up in remaining partic-
ipants was not clear (Lindor 2009). A total of 11 trials (706
participants) provided data for one or more outcomes (Allison
1986; LaRusso 1988; Sandborn 1993; Olsson 1995; Farkkila
2004; Olsson 2005; Cullen 2008; Hommes 2008; Lindor 2009;
Tabibian 2013; Rahimpour 2016). Trials did not provide infor-
mation on whether participants were symptomatic. Similarly, tri-
als did not report whether people with inflammatory bowel dis-
ease were included, although one trial excluded participants with
severe inflammatory bowel disease or required specific treatment
other than mesalazine (Hommes 2008). Information on potential
effect modifiers such as presence of symptoms and proportion of
participants with inflammatory bowel disease was missing from
many trials.
Table 1 presents the intervention and control used in these trials
and risk of bias arranged according to each pair-wise comparison.
Source of funding: Fifteen trials reported the source of funding;
three were funded by parties without vested interest in results of
the trial (Allison 1986; Tabibian 2013; Rahimpour 2016), and
12 were funded in part or in full by the pharmaceutical industry
(LaRusso 1988; Beuers 1992; Sandborn 1993; Knox 1994; Lindor
1997; Farkkila 2004; Sterling 2004; Olsson 2005; Cullen 2008;
Hommes 2008; Lindor 2009; Trauner 2016).
Excluded studies
Of 37 excluded studies, we excluded 16 because they were
not randomised clinical trials (Wagner 1971; Stiehl 1989a;
Tabibian 1989; Stiehl 1994; Lindor 1995; Stiehl 1996; Eisenburg
1997; Harnois 2001; Kurihara 2003; Lankarani 2003; Chapman
2005; Lindor 2005; Tada 2006; Silveira 2008; Lindor 2009a;
Imam 2011); seven because they provided comments on ran-
domised clinical trials and other published experiences (Fromm
1992; Goldberg 1992; Gross 1993; Spengler 1993; Beuers 1998;
Lankarani 2005; Triantos 2012); and one because it was an edito-
rial (Chapman 2009). We excluded one study because it was con-
ducted to examine non-pharmacological agents (Vleggaar 2008).
One study investigated an intervention that was not targeted at
control of primary sclerosing cholangitis (Vleggaar 2001). In three
trials, participants in different arms received the same pharma-
cological agent in different doses (Stiehl 1994a; van Hoogstraten
1998; van Hoogstraten 2000), and one study did not provide sep-
arate data for trial participants in the control group who received
colchicine or no intervention (Van Thiel 1992). Therefore, we ex-
cluded these studies. We excluded one study because people with
liver transplantation were included (Hay 2001) and we excluded
six trials on cholestatic liver disease because investigators did not
provide separate data for trial participants with primary sclerosing
cholangitis (van deMeeberg 1996; Vleggaar 2001; Ter Borg 2004;
Villamil 2005; Mayo 2007; Kuiper 2010).
Risk of bias in included studies
We have summarised the risk of bias in included trials in Figure 2
and Figure 3. Except for one small trial including 29 participants
who were followed-up for 12 weeks, at the end of which none
had died or developed treatment-related or disease-related adverse
events (Rahimpour 2016), all trials were at high risk of bias.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six trials (27.3%) had adequate sequence generation (Beuers
1992; Lindor 1997; Farkkila 2004; Cullen 2008; Lindor 2009;
Rahimpour 2016). The remaining 16 trials did not report the se-
quence generation and were considered to be at unclear risk of
sequence generation bias.
Seven trials (31.8%) had adequate allocation concealment (Allison
1986; Farkkila 2004; Sterling 2004; Olsson 2005; Cullen 2008;
Lindor 2009; Rahimpour 2016). The remaining 15 trials did not
report the allocation concealment and were considered to be at
unclear risk of allocation concealment bias.
Thus, four trials (18.2%) had low risk of selection bias (Farkkila
2004; Cullen 2008; Lindor 2009; Rahimpour 2016). The remain-
ing 21 trials were at unclear risk of bias.
Blinding
Fifteen trials (68.2%) reported adequate blinding of participants,
personnel, and outcome assessors and were at low risk of per-
formance and detection biases (Allison 1986; LaRusso 1988;
Beuers 1992; Sandborn 1993; Knox 1994; Olsson 1995; Lindor
1997; Mitchell 2001; Farkkila 2004; Olsson 2005; Cullen 2008;
Hommes 2008; Lindor 2009; Tabibian 2013; Rahimpour 2016).
Two trials were at high risk of performance bias (De Maria 1996;
Sterling 2004), as one group of participants in one trial did not
receive any intervention (De Maria 1996), and participants or in-
vestigators in the other trial were not blinded to the intervention
(Sterling 2004). The remaining five trials were at unclear risk of
performance bias. One trial was at high risk of detection bias, as
investigators were not blinded to the intervention in another trial
(Sterling 2004). The remaining trials were at unclear risk of per-
formance bias and detection bias.
Incomplete outcome data
Only three of the 22 trials (13.6%)were free frombias owing to in-
complete outcome data (Mitchell 2001; Lindor 2009; Rahimpour
2016). Post-randomisation drop-outs may be related to the in-
tervention in 12 trials; therefore, we considered these 12 trials
to be at high risk of bias (Allison 1986; Stiehl 1989; Lo 1992;
Sandborn 1993; Knox 1994; Bansi 1996; Lindor 1997; Farkkila
2004;Olsson2005;Cullen2008;Hommes 2008;Tabibian 2013).
Participant flow was not available for the remaining seven trials;
therefore, we considered these seven trials to be at unclear risk of
bias (LaRusso 1988; Beuers 1992; Olsson 1995; De Maria 1996;
Rasmussen 1998; Sterling 2004; Trauner 2016).
Selective reporting
A pre-published protocol was not available for any trial. Only
six trials (27.3%) reported mortality and liver transplantation;
hence we considered these trials to be free from reporting bias
(Allison 1986; LaRusso 1988; Olsson 1995; Olsson 2005; Lindor
2009; Rahimpour 2016). We considered the remaining trials to
be at high risk of bias, as they reported neither mortality nor liver
transplantation.
Other potential sources of bias
Thirteen trials (68.4%) reported the source of funding, and we
rated for-profit bias as low in only three of these (13.6%) (Allison
1986; Tabibian 2013; Rahimpour 2016). Twelve trials were at
high risk of for-profit bias because they were funded in part or
in full by pharmaceutical industries with vested interest in study
results (LaRusso 1988; Beuers 1992; Sandborn 1993; Knox 1994;
Lindor 1997; Farkkila 2004; Sterling 2004; Olsson 2005; Cullen
2008; Hommes 2008; Lindor 2009; Trauner 2016).
Effects of interventions
See: Summary of findings for the main comparison
Ursodeoxycholic acid versus placebo for primary sclerosing
cholangitis
Mortality
Six trials (542 participants) provided data on mortality (Allison
1986, LaRusso 1988; Olsson 1995; Olsson 2005; Lindor 2009;
Rahimpour 2016).Mortality was reported at different time points;
therefore, we have analysed mortality at maximal follow-up. Me-
dian follow-up times in these six trials were:
• 0.25 year (Allison 1986);
• 4 years (LaRusso 1988);
• 3 years (Olsson 1995);
• 14 years (Olsson 2005);
• 3 years (Lindor 2009); and
• 0.25 year (Rahimpour 2016).
As shown in Analysis 1.1, studies provided no evidence of differ-
ences in any comparisons.
• Colchicine versus placebo: odds ratio 0.44, 95% CI 0.04 to
5.07, participants = 84, one trial.
• Penicillamine versus placebo: odds ratio 1.18, 95% CI 0.39
to 3.58, participants = 70, one trial.
• Steroids versus placebo: odds ratio 3.00, 95% CI 0.10 to
90.96, participants = 11, one trial.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
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• Ursodeoxycholic acid versus placebo: odds ratio 1.51, 95%
CI 0.63 to 3.63, participants = 348, two trials, I2 = 0%.
Studies found no evidence of heterogeneity for ursodeoxycholic
acid versus placebo (I2 = 0; Chi2 test for heterogeneity P = 0.87).
Analysis revealed no differences in interpretation of results when
the fixed-effect versus the random-effects model was used for com-
parison.
Proportion of people with serious adverse events
Three trials (47 participants) provided data on proportions of
participants with serious adverse events (Allison 1986; Hommes
2008; Rahimpour 2016). Analysis 1.2shows no differences in any
of these comparisons.
• Infliximab versus placebo: odds ratio not estimable (because
of zero events in both arms), participants = 7, one trial.
• Steroids versus placebo: odds ratio 20.00, 95% CI 0.93 to
429.90, participants = 11, one trial.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
Lindor 2009 did not report the proportion of participants with
serious adverse events; however, trial authors stated that “serious
adverse events were more with UDCA group”.
Number of serious adverse events
Three trials (88 participants) provided data on numbers of serious
adverse events (Allison 1986; LaRusso 1988; Hommes 2008).
Analysis 1.3 shows no differences in any of these comparisons.
• Infliximab versus placebo: rate ratio 0.80, 95% CI 0.02 to
40.44, participants = 7, one trial.
• Penicillamine versus placebo: rate ratio 13.60, 95% CI 0.78
to 237.83, participants = 70, one trial.
• Steriods versus placebo: rate ratio 3.32, 95% CI 0.71 to
15.62, participants = 11, one trial.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
Proportion of people with adverse events
Three trials (238 participants) provided data on proportions of
participants with adverse events (Allison 1986; Olsson 2005;
Rahimpour 2016). Analysis 1.4 shows no differences in any of
these comparisons.
• Steroids versus placebo: odds ratio 20.00, 95% CI 0.93 to
429.90, participants = 11, one trial.
• Ursodeoxycholic acid versus placebo: odds ratio 1.22, 95%
CI 0.68 to 2.17, participants = 198, one trial.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
Number of total adverse events
Five trials (207 participants) reported the number of adverse events
(Allison 1986; LaRusso 1988; Sandborn 1993; Farkkila 2004;
Tabibian 2013). As shown in Analysis 1.5, the number of adverse
events was higher with penicillamine versus placebo (rate ratio
2.48, 95% CI 1.18 to 5.23, participants = 70, one trial) and with
vancomycin versus metronidazole (rate ratio 0.41, 95%CI 0.19 to
0.87, 29 participants, one trial). Analysis revealed no differences
in any of the remaining comparisons.
• Cyclosporin versus placebo: rate ratio 2.64, 95% CI 0.99 to
7.03, participants = 26, one trial.
• Steroids versus placebo: rate ratio 3.32, 95% CI 0.71 to
15.62, participants = 11, one trial.
• Ursodeoxycholic acid plus metronidazole versus
ursodeoxycholic acid: rate ratio 2.36, 95% CI 0.98 to 5.71,
participants = 71, one trial.
Quality of life
Only one trial estimated quality of life using a validated scale
(Olsson 2005). Investigators found no evidence of differences be-
tween the mean value of the SF-36 General Health Scale in ur-
sodeoxycholic acid versus placebo groups (mean difference 1.30,
95%CI -5.61 to 8.21, participants = 198, one trial) after a median
follow-up of five years (Analysis 1.6).
Liver transplantation
Seven trials (613 participants) reported liver transplantation
(Allison 1986; LaRusso 1988;Olsson 1995; Farkkila 2004;Olsson
2005; Lindor 2009; Rahimpour 2016). Liver transplantation was
reported at different time points; therefore, we analysed liver trans-
plantation at maximal follow-up. Median follow-up times in these
six trials were:
• 0.25 year (Allison 1986);
• 4 years (LaRusso 1988);
• 3 years (Olsson 1995);
• 3 years (Farkkila 2004);
• 14 years (Olsson 2005);
• 3 years (Lindor 2009); and
• 0.25 year (Rahimpour 2016).
Analysis 1.7 shows no differences in any of these comparisons.
• Colchicine versus placebo: odds ratio 0.59, 95% CI 0.09 to
3.71, participants = 84, one trial.
• Penicillamine versus placebo: odds ratio 1.18, 95% CI 0.39
to 3.58, participants = 70, one trial.
• Steroids versus placebo: odds ratio not estimable (zero
events in both groups), participants = 11, one trial.
• Ursodeoxycholic acid versus placebo: odds ratio 0.97, 95%
CI 0.52 to 1.81, participants = 348, two trials, I2 = 74%.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
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• Ursodeoxycholic acid plus metronidazole versus
ursodeoxycholic acid: odds ratio 0.29, 95% CI 0.03 to 2.90,
participants = 71, one trial.
Evidence shows heterogeneity in the ursodeoxycholic acid versus
placebo group (I2 = 74%, Chi2 test for heterogeneity P = 0.05)
and no difference in interpretation of results for fixed-effect versus
random-effects models for this comparison.
Decompensated liver disease
One trial (29 participants) reported no decompensated liver dis-
ease in the vancomycin group nor in the placebo group after three
months of follow-up (Rahimpour 2016). None of the remaining
trials reported this information adequately for analysis of data.
Any malignancy
One trial (29 participants) reported no malignancy in the van-
comycin group nor in the placebo group after three months of fol-
low-up (Rahimpour 2016). None of the remaining trials reported
this information adequately for analysis of data.
Cholangiocarcinoma
Four trials (403 participants) reported the proportion of cholan-
giocarcinoma (Sandborn 1993; Olsson 2005; Lindor 2009;
Rahimpour 2016). Analysis 1.8 shows no differences in any of
these comparisons.
• Cyclosporin versus placebo: odds ratio 0.19, 95% CI 0.01
to 5.20, participants = 26, one trial.
• Ursodeoxycholic acid versus placebo: odds ratio 1.34, 95%
CI 0.48 to 3.68, participants = 348, two trials, I2 = 0%.
• Vancomycin versus placebo: odds ratio not estimable,
participants = 29, one trial.
Evidence shows no heterogeneity in the ursodeoxycholic acid ver-
sus placebo group (I2 = 0, Chi2 test for heterogeneity P = 0.13) and
no difference in interpretation of for fixed-effect versus random-
effects models for this comparison.
Colorectal cancer
One trial (29 participants) reported no colorectal cancer in the
vancomycin group nor in the placebo group after three months
of follow-up (Rahimpour 2016). None of the remaining trials
reported this information adequately for analysis of data.
Cholecystectomy
None of the included trials reported this information.
Subgroup analysis
We were unable to perform any subgroup analysis because of the
paucity of data.However, wewere able to perform an analysis strat-
ified by doses of UDCA (low, moderate, or high) (Analysis 2.1;
Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5; Analysis 2.6;
Analysis 2.7; Analysis 2.8).We included all studies with the excep-
tion of Cullen 2008 in both the main analysis and the stratified
analysis. Cullen 2008 compared three different doses of UDCA
without including any other control. So we included this trial only
in the stratified analysis and stratified the UDCA dose. The strat-
ified analysis did not change our interpretation of results.
Sensitivity analysis
We did not perform the planned sensitivity analysis because data
were sparse, and because we did not impute the mean or the stan-
dard deviation for continuous outcomes.
Trial Sequential Analysis
Only three comparisons included more than one trial under the
outcome.
• Mortality at maximal follow-up: UDCA versus placebo.
• Liver transplantation: UDCA versus placebo.
• Cholangiocarcinoma: UDCA versus placebo.
On the basis of an alpha error of 2.5%, power of 90% (beta error
of 10%), relative risk reduction of 20%, control group proportion
observed in trials (mortality at maximal follow-up: 7.2%; liver
transplantation: 12.3%; and cholangiocarcinoma 4.3%), and het-
erogeneity observed in analyses, required information sizes were
14,509; 34,179; and 24,972. As shown in Figure 4, only a small
fraction of the required information size was reached and trial
sequential monitoring boundaries were not drawn. The Z-curve
did not cross any boundaries. This indicates that risk of random
error is high for all outcomes included in this review. We could
not calculate trial sequential adjusted boundaries because sample
sizes in these trials were small.
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Figure 4. Based on an alpha error of 2.5%, power of 90% (beta error of 10%), relative risk reduction (RRR) of
20%, control group proportion observed in the trials (Pc), and heterogeneity observed in the analyses, only a
small fraction of the diversity-adjusted required information size (DARIS) has been reached (required
information size = 348; DARIS = 14,509 for mortality at maximal follow-up; required information size = 348;
DARIS = 35,846 for liver transplantation; required information size = 348; DARIS = 29,191 for
cholangiocarcinoma), and trial sequential monitoring boundaries were not drawn. The Z-curves (blue lines) do
not cross conventional boundaries (dotted green lines). This indicates high risk of random errors for all
outcomes included in this review.
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Quality of evidence
The overall quality of evidence was low or very low for all outcomes
unless otherwise indicated. We downgraded the quality of evi-
dence because of risk of bias (downgraded by two levels) for most
comparisons, imprecision (small sample size: downgraded by one
level), imprecision (wide confidence intervals: downgraded by one
level), and inconsistency (downgraded by two levels) (Summary
of findings for the main comparison). Ursodeoxycholic acid was
the only comparison performed by at least two trials; we have pre-
sented this in Summary of findings for the main comparison. The
remaining comparisons are presented in the text.
D I S C U S S I O N
Summary of main results
In this systematic review of pharmacological interventions for
people with primary sclerosing cholangitis, we included 22 ran-
domised clinical trials, 10 of which provided information on one
or more outcomes of interest for this review. We found no evi-
dence of differences between any of the interventions and placebo
for important clinical benefits such as reduction in mortality at
maximal follow-up, improvement in health-related quality of life,
reduction in the requirement for liver transplantation, or reduc-
tion in the incidence proportion of cholangiocarcinoma. Other
important clinical benefits such as incidence proportion of all ma-
lignancies, colorectal cancer, liver decompensation, time to liver
decompensation, time to liver transplantation, and requirement
for cholecystectomy were not reported clearly enough in any of
the included trials to allow comparison of different interventions.
However, it should be pointed out that primary sclerosing cholan-
gitis is a slowly progressive disease, and that follow-up in these tri-
als was short. Future trials should provide a follow-up period of 10
years or longer and should include important clinical outcomes.
Overall completeness and applicability of
evidence
This review included randomised clinical trials in people with
primary sclerosing cholangitis. Trials applied few restrictions apart
from an established diagnosis of primary sclerosing cholangitis,
evidence of cholestasis, absence of decompensated liver disease,
and absence of malignancy. Therefore, the findings of this review
are applicable to most people with primary sclerosing cholangitis
without decompensated liver disease.
Quality of the evidence
The overall quality of evidence was very low. Risk of bias was
unclear or high in all included trials. Selection bias was related
mainly to unclear description of random sequence generation and
of allocation concealment. Appropriate methods of randomisa-
tion and adequate reporting of the method of randomisation used
will decrease selection bias. Most of the performance bias detected
was due to missing, incomplete, or unclear information. A more
detailed description of blinding will improve the quality of evi-
dence. Drop-outs were due mainly to participants’ lack of com-
pliance (missing follow-up, treatment discontinuation, or with-
drawal of consent). This reflects the real-life situation in which
lack of compliance with treatment is prevalent, and because the
primary aim of researchers is to recommend or not recommend a
specific treatment (or combination of treatments), an intention-
to-treat analysis should be performed to avoid a biased estimate of
treatment effect. Currently, no validated surrogate outcomes have
been used to evaluate interventions for people with primary scle-
rosing cholangitis (Ponsioen 2016). Reporting all important clin-
ical outcomes with appropriate follow-up can decrease selective
reporting bias. Funding from parties without vested interest in the
results or at least publication of a full protocol before recruitment
along with adherence to Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines (Chan 2013)
and theConsolidated Standards of Reporting Trials (CONSORT)
statement (Schulz 2010) in the final report will decrease risk of
bias in these trials.
Results showed imprecision of treatment effects for all outcomes
because of small sample size, along with wide confidence intervals
that overlap no effect and clinically significant improvement or
deterioration or both. Overall, the quality of evidence was very
low (Summary of findings for the main comparison).
Potential biases in the review process
We followed guidance provided in the Cochrane Handbook for
Systematic Reviews of Interventions. Two review authors indepen-
dently selected studies and extracted data. We performed a thor-
ough search of the literature. However, the search period included
the pre-mandatory trial registration era, and some trials on inter-
ventions that were not effective or were harmful may not have
been reported at all.
A major limitation of this review was the high risk of bias in in-
cluded trials, resulting in low or very low quality of evidence. An-
other major limitation of this review was the paucity of available
data. We included few trials under each comparison. Many com-
parisons included only one trial, making it difficult for review au-
thors to assess whether effect estimates are reproducible, and mak-
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ing assessment of inconsistency underpowered in comparisons in-
volving more than one trial. Lack of evidence of inconsistency
should not be considered synonymous with lack of inconsistency.
This paucity of data decreases confidence in the results.
We excluded studies that compared variations among different
interventions. Hence, this review has not provided information
on whether one variation is better than another.
We included only randomised clinical trials known to focus on
benefits without collecting and reporting harms in a detailedman-
ner. Our choice of studies for inclusion (i.e. only randomised clin-
ical trials) might have caused us to miss a large number of stud-
ies that addressed reporting of harms. Accordingly, this review is
biased towards focusing on benefits and ignoring harms. We did
not search for interventions and trials registered at regulatory au-
thorities (e.g. FDA (US Food and Drug Administration); EMA
(European Medicines Agency)). This may have led us to overlook
trials; as such trials usually are unpublished, lack of their inclusion
may make our comparisons appear more advantageous than they
really are. However, this topic is of academic interest only because
study results show no evidence of benefit of any intervention for
people with primary biliary cholangitis (i.e. there is no reason to
suggest that any interventions should be used in routine clinical
practice regardless of their adverse event profile).
We planned to perform a network meta-analysis. However, it was
not possible to assess whether potential effect modifiers such as
presence of symptoms and presence of inflammatory bowel dis-
ease were similar across different comparisons, and performing a
network meta-analysis in this scenario can be misleading. There-
fore, we did not perform the network meta-analysis but instead
assessed comparative benefits and harms of different interventions
using standard Cochrane methods.
Agreements and disagreements with other
studies or reviews
A few systematic reviews have examined pharmacological inter-
ventions for primary sclerosing cholangitis; all have evaluated sin-
gle classes of drugs. Owing to the cholestatic nature of the dis-
ease, bile acids have always been given particular attention in
primary sclerosing cholangitis and their use has been evaluated
in another Cochrane systematic review (Poropat 2011). This re-
view concluded that evidence was insufficient to support or re-
fute clinical effects of ursodeoxycholic (UDCA)/bile acids in pa-
tients with primary sclerosing cholangitis. Another meta-analysis
of randomised clinical trials comparing standard or high doses of
UDCA (> 15 mg/kg body weight per day) versus placebo or no
intervention in primary sclerosing cholangitis found that neither
standard nor high doses of UDCA favourably influence progres-
sion of primary sclerosing cholangitis (Triantos 2011). In fact, re-
view authors found no significant differences in outcomes (mortal-
ity, cholangiocarcinoma, histology stage progression) nor in symp-
toms (pruritus and fatigue) between the group treatedwithUDCA
and the placebo/untreated group (Triantos 2011). However, a pa-
per (Tabibian 2014) published after analysis of the available liter-
ature including an uncontrolled trial reporting negative effects of
UDCA withdrawal on the biochemical and symptomatic picture
of patients with primary sclerosing cholangitis (Wunsch 2014) ar-
gued for potential reconsideration of the use of UDCA in primary
sclerosing cholangitis.
One Cochrane systematic review has explored the use of glucocor-
ticosteroids for primary sclerosing cholangitis (Giljaca 2010). This
review concluded that no evidence was available to support or re-
fute oral glucocorticosteroids for patients with primary sclerosing
cholangitis, and that intrabiliary application of corticosteroids via
a nasobiliary tube seemed to induce severe adverse effects (Giljaca
2010).
This Cochrane systematic review identified only one randomised
trial examining D-penicillamine for primary sclerosing cholangitis
(Klingenberg 2006). Results showed that D-penicillamine had no
significant effect on mortality nor on liver transplantation.
The present systematic review is the first to include all pharmaco-
logical interventions for primary sclerosing cholangitis. Our con-
clusions reflect and summarise those reported in the up-to-date
evidence-based literature: Effective medical treatment for primary
sclerosing cholangitis is not available.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence is currently insufficient to show differences in effective-
ness measures such as mortality, health-related quality of life, cir-
rhosis, or liver transplantation between any active pharmacologi-
cal intervention versus no intervention. However, confidence in-
tervals were wide and follow-up was short; therefore, important
clinical benefits or harms could not be ruled out.
Implications for research
The timing of this report is important, as we are entering a period
when clinical trials are evaluating several new potential treatments
for primary sclerosing cholangitis. An understanding of the lim-
itations of previous studies will guide researchers as they design
current and future studies. We have identified an urgent need for
effective medical intervention for patients with primary sclerosing
cholangitis. Currently, the three compartments providing treat-
ment targets for clinical trials are bile acid manipulation, biolog-
ical modulators of immune cell activation, and recruitment and
antifibrotic therapies. High-quality randomised clinical trials de-
signed to measure clinically important differences in accordance
with SPIRIT (Standard Protocol Items: Recommendations for In-
terventional Trials; Chan 2013) and CONSORT (Consolidated
Standards of Reporting Trials) guidelines (Schulz 2010) are nec-
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essary. However, researchers must take into account specific con-
siderations regarding primary sclerosing cholangitis as they design
future trials, including the rarity and phenotypical heterogeneity
of the disease, its prolonged natural history, our limited under-
standing of risk stratification, and the lack of validated surrogate
endpoints and quality of life/patient-reported outcome measures
for this disorder. Aspects of trial design that need to be addressed
in future studies include:
• ensuring that patients recruited into trials are
phenotypically similar across randomised groups, and that
biological plausibility can be found for the treatment under
evaluation in the cohort of patients studied;
• stratifying risk of trial participants to ensure balance in trial
groups while reducing the risk of type 1 and 2 errors;
• embedding several exploratory endpoints into the design to
assess whether these are good surrogate outcomes; and
• appropriately powering studies with adequate follow-up
with potential to conduct record linkage studies to identify long-
term effects of interventions for primary sclerosing cholangitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allison 1986
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 17.
Post-randomisation drop-outs: 6 (35.3%).
Revised sample size: 11.
Mean age: 52 years.
Females: 3 (27.3%).
Ulcerative colitis: no.
Inclusion criteria:
1. Primary sclerosing cholangitis of the intrahepatic ducts.
Exclusion criteria:
1. Biliary bypass procedure.
Follow-up: 3 months after completion of 2-week treatment.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: continuous nasobiliary irrigation with normal saline plus hydrocortisone (100
mg/d) for 2 weeks (n = 6).
Group 2: continuous nasobiliary irrigation with saline alone (1 L/d) for 2 weeks (n = 5)
Outcomes 1. Mortality.
2. Proportion of participants with any type of adverse events.
3. Proportion of participants with severe adverse events.
4. Number of any type of adverse events.
5. Number of severe adverse events.
6. Liver transplantation.
Notes Reasons for post-randomisation drop-out: “technical failures”:
1. Endoscopic retrograde cholangiopancreatography failure (n = 2).
2. Nasobiliary tube insertion failure (n = 2).
3. Nasobiliary tubes fell out of the biliary tree during lavage (n = 2).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised by sealed envelope to
receive continuous nasobiliary irrigation with either normal
saline alone or normal saline plus hydrocortisone. [.] The
randomisation codewas blocked to ensure an approximately
equal number of patients in each group at any stage of the
trial”
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Allison 1986 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised by sealed envelope”.
Comment: “Opaque sealed envelopes manually shuffled”
(trial author’s reply)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients and interpreters blinded to allocation”
(trial author’s reply)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients and interpreters blinded to allocation”
(trial author’s reply)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and liver transplantation were reported
For-profit bias Low risk Comment: “Patients were cared for and followed within
normal NHS founded hospital stay. No additional grants
were sought” (trial author’s reply)
Other bias Low risk Comment: no other bias.
Bansi 1996
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 23.
Post-randomisation drop-outs: 1 (4.3%).
Revised sample size: 22.
Mean age: 53 years.
Females: 7 (31.8%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis.
2. Pre-trial biopsy and cholangiography.
Exclusion criteria: not stated.
Follow-up: 12 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: moderate-dose UDCA (20 mg/kg/d) over the period of follow-up of the study
(n = 11).
Group 2: placebo over the period of follow-up of the study (n = 11)
Outcomes No outcomes of interest were reported.
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Bansi 1996 (Continued)
Notes Reasons for post-randomisation drop-out:
1. Dominant bile duct stricture that required stenting (UDCA group).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Double-blind placebo-controlled trial”.
Comment: Further details were not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) Unclear risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
Beuers 1992
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 14.
Post-randomisation drop-outs: unclear.
Revised sample size: 14.
Mean age: 39 years.
Females: 3 (21.4%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis by endoscopic retrograde
cholangiography, hepatobiliary histological appearance, and a cholestatic serum
enzyme pattern in the absence of evidence of secondary sclerosing cholangitis,
hepatobiliary malignancies, or other viral, metabolic, or autoimmune liver disease.
2. Alkaline phosphatase level at least 1.5 times above the normal value (≤ 190 U/L).
Exclusion criteria:
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Beuers 1992 (Continued)
1. Pregnancy.
2. Therapy for primary sclerosing cholangitis within the past 3 months with UDCA,
azathioprine, chlorambucil, colchicine, cyclosporine, methotrexate, D-penicillamine,
or corticosteroids.
3. Serum bilirubin level higher than 15 mg/dL (255 pmol/L).
4. Other liver disease in addition to primary sclerosing cholangitis.
Follow-up: 12 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose UDCA (13-15 mg/kg/d) over the period of follow-up of the study
(n = 6).
Group 2: identical-appearing placebo over the period of follow-up of the study (n = 8)
Outcomes No outcomes of interest were reported.
Notes Reasons for post-randomisation drop-out:
1. Occurrence of serious side effects potentially attributable to the therapy.
2. Suspected carcinoma.
3. Decompensation of liver disease requiring liver transplantation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned with a computer generated
block randomisation to receive UDCA or identical-appear-
ing placebo”
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study was a double-blind, randomized trial
comparing the efficacy and safety of UDCA with that of
placebo treatment…… Patients were assigned with a com-
puter generated block randomization to receive UDCA or
identical appearing placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study was a double-blind, randomized trial
comparing the efficacy and safety of UDCA with that of
placebo treatment…… Patients were assigned with a com-
puter generated block randomization to receive UDCA or
identical appearing placebo”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: Two patients (1 for each group) were excluded
from the analysis (withdrawal), but adverse events were re-
ported
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
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Beuers 1992 (Continued)
For-profit bias High risk Quote: “Patients were assigned with a computer generated
block randomization to receive UDCA or identical appear-
ing placebo in 250-mg capsules (13 to 15 mg/kg body wt/
day; provided by Dr. Falk GmbH, Frei-burg, Germany)”
Comment: The trial was funded by a party with a vested
interest in the results
Other bias Low risk Comment: no other bias.
Cullen 2008
Methods Randomised clinical trial.
Participants Country: UK/Germany.
Number randomised: 33.
Post-randomisation drop-outs: 2 (6%).
Revised sample size: 31.
Mean age: 47 years.
Females: 8.
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Age older than 18 years.
2. Clinical, biochemical, and radiological features of primary sclerosing cholangitis.
3. Increased activity of alkaline phosphatase or gamma-glutamyltransferase at the
beginning of the study.
4. Liver histology compatible with primary sclerosing cholangitis.
Exclusion criteria:
1. Previous biliary tract surgery (excluding simple cholecystectomy).
2. Major extrahepatic or hilar duct stricture causing jaundice.
3. Cholangiocarcinoma.
4. Decompensated liver disease.
5. Antimitochondrial antibody (AMA) positive.
6. Pregnancy or breastfeeding.
7. Women of childbearing age not using safe contraception.
Follow-up: 24 months.
Interventions Participants were randomly assigned to 1 of 3 groups.
Group 1: low-dose UDCA (10 mg/kg/d) plus placebo over the period of follow-up of
the study (n = 11).
Group 2: moderate-dose UDCA (20 mg/kg/d) plus placebo over the period of follow-
up of the study (n = 11)
Group 3: high-dose UDCA (30 mg/kg/d) over the period of follow-up of the study (n
= 9)
Outcomes 1. Number of any type of adverse events.
2. Number of severe adverse events.
3. Liver transplantation.
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Cullen 2008 (Continued)
Notes Reasons for post-randomisation drop-out:
1. Participants were terminated from the study prematurely.
2. No data were given other than data from the baseline visit.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “This randomisation was carried out by an inde-
pendent blinded trial pharmacist in each centre using a pre-
determined randomisation scheme. Patient numbers were
issued sequentially within a centre”
Allocation concealment (selection bias) Low risk Quote: “This randomisation was carried out by an inde-
pendent blinded trial pharmacist in each centre using a pre-
determined randomisation scheme. Patient numbers were
issued sequentially within a centre”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A proportion of the capsules taken by patients in
the low and standard dose arms of the trials were placebos.
The trial was a randomised, double blinded, dose-finding
study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A proportion of the capsules taken by patients in
the low and standard dose arms of the trials were placebos.
The trial was a randomised, double blinded, dose-finding
study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Dr. Falk Pharma (Freiburg, Germany) provided
drugs and placebos for this trial as well as financial support
for the statistical calculations performed at ClinResearch
(Koln, Germany), an independent institute for biostatistics
of clinical trials”
Comment: The trial was funded by a party with vested
interest in the results
Other bias Low risk Comment: no other bias.
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De Maria 1996
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 59.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 59.
Mean age: 31 years.
Females: 17 (28.8%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Primary sclerosing cholangitis documented by endoscopic cholangiography, liver
biopsy, and a battery of clinical, biochemical, and serological parameters.
Exclusion criteria: not stated.
Follow-up: 24 months.
Interventions Participants were randomly assigned to 1 of 3 groups.
Group 1: low-dose UDCA (300 mg twice a day) over the period of follow-up of the
study (n = 20).
Group 2: colchicine (60 mg twice a day) over the period of follow-up of the study (n =
19)
Group 3: no active intervention (n = 20).
Outcomes No outcomes of interest were reported.
Notes “No statistical differences in the various outcome measures for the colchicine and the
untreated group were evident after 2 years of follow-up. As a result, these data were
collapsed as a single controlled group (n = 39) and were compared against the UDCA
group (n = 20)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: A group of participants received no treatment.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
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De Maria 1996 (Continued)
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
Farkkila 2004
Methods Randomised clinical trial.
Participants Country: Finland.
Number randomised: 80.
Post-randomisation drop-outs: 9 (11.3%).
Revised sample size: 71.
Mean age: 39 years.
Females: 38 (53.6%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Confirmed diagnosis of primary sclerosing cholangitis by both liver histology and
endoscopic retrograde cholangiopancreatography.
2. Age between 16 and 65 years.
Exclusion criteria:
1. End-stage liver disease with decompensation (ascites not easily controlled by
diuretics, Child-Pugh C).
2. Other coexisting liver disease.
3. Suspected cholangiocarcinoma.
4. Suspected or documented malignancy.
5. Recurrent ascending cholangitis requiring antibiotic therapy.
6. Pregnancy.
Follow-up: 36 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose UDCA (15 mg/kg/d) and placebo over the period of follow-up of
the study (n = 37)
Group 2: low-dose UDCA (15 mg/kg/d) and metronidazole 600 to 800 mg/d over the
period of follow-up of the study (n = 34)
Outcomes 1. Number of any type of adverse events.
2. Liver transplantation.
Notes Reasons for post-randomisation drop-out:
1. Overlapping syndrome with autoimmune hepatitis (3 participants).
2. Liver transplantation (3 participants in the UDCA/placebo group, 1 participant
in the UDCA/metronidazole group).
3. Development of cholangiocarcinoma (2 participants in the UDCA/placebo
group).
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Farkkila 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was done centrally with computer
generated blocks”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was done centrally with computer
generated blocks”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “In this multicenter, randomized, double-blind,
placebo-controlled trial, the patients were randomized ei-
ther to UDCA and placebo (n = 41) or UDCA and MTZ
(n = 39)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “In this multicenter, randomized, double-blind,
placebo-controlled trial, the patients were randomized ei-
ther to UDCA and placebo (n = 41) or UDCA and MTZ
(n = 39). Endoscopic retrograde cholangiopancreatography
findings were analysed by two radiologists independently,
specialised in hepatobiliary disease, and blinded to clinical
data and the order of examinations”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Mary and Georg C. Ehnrooth Foundation.
Medicationswere supplied, free of charge, byOrionPharma
and Leiras, Finland”
Comment: The trial was funded by a party with vested in-
terest in the results: Orion Pharma producesmetronidazole,
and Leiras produces UDCA
Other bias Low risk Comment: no other bias.
Hommes 2008
Methods Randomised clinical trial.
Participants Country: The Netherlands.
Number randomised: 10.
Post-randomisation drop-outs: 3 (30%).
Revised sample size: 7.
Mean age: 45 years.
Females: 4 (57.1%).
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Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Cholangiographic or histological diagnosis of primary sclerosing cholangitis.
2. Age older than 18 years.
3. Alkaline phophatase at least 2 times the upper limit of normal.
Exclusion criteria:
1. Crohn’s disease activity index greater than 350.
2. Evidence of secondary sclerosing cholangitis.
3. Evidence of other liver disease.
4. Previous treatment with infliximab, treatment with any other agent targeted at
tumour necrosis factor (TNF) reduction within 3 months of screening, treatment with
immunosuppressive or anti-inflammatory medication other than mesalazine
derivatives.
5. Unstable on treatment with UDCA.
Follow-up: 13 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: infliximab (5 mg/kg) at weeks 0, 2, 6, 12, 18, and 24 (n = 4)
Group 2: placebo at weeks 0, 2, 6, 12, 18, and 24 (n = 3).
Outcomes 1. Proportion of participants with severe adverse events
2. Number of severe adverse events.
Notes Reasons for post-randomisation drop-out:
1. Liver transplantation (1 participant in the placebo group).
2. Dominant stenosis requiring stenting (1 participant in the infliximab group).
3. Colorectal cancer (1 participant in the infliximab group).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised in a 2:1 ratio to receive
infliximab or placebo at weeks 0, 2, 6,12, 18, and 24”
Comment: Additional details were not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Infliximab was supplied in 20-mL vials containing
100mg of the lyophilized concentrate; placebo was identi-
cally formulated. The infusion solution was administered
by blinded investigators using an infusion set”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Infliximab was supplied in 20-mL vials containing
100mg of the lyophilized concentrate; placebo was identi-
cally formulated. The infusion solution was administered
by blinded investigators using an infusion set”
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Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Daan Hommes has served as consultant and
speaker for both Centocor and Schering Plough. Supported
by a Research Grant from Centocor, Inc (Malvern, USA)”
Comment: The trial was funded by a party with vested
interest in the results (this company produces infliximab)
Other bias Low risk Comment: no other bias.
Knox 1994
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 24.
Post-randomisation drop-outs: 3 (12.5%).
Revised sample size: 21.
Mean age: 37 years.
Females: 7 (33.3%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Primary sclerosing cholangitis documented by characteristic findings on
endoscopic retrograde cholangiopancreatography and liver biopsy.
Exclusion criteria:
1. Cytopenia (white blood cell count < 4000 cells/mm3, platelets < 100,000 cells/
mm3, or haemoglobin < 10.0 g/dL).
2. Significant cardiac or renal disease (serum creatinine > 2 mg/dL).
3. Pregnancy, lactation, or lack of effective contraceptive methods.
4. Alcoholism.
5. Signs of liver failure manifested by ascites, encephalopathy, variceal bleeding, or
muscle wasting.
6. Dominant common bile duct strictures.
Follow-up: 48 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: methotrexate 5 mg every 12 hours (15 mg/wk) for 24 months (n = 11)
Group 2: identical placebo for 24 months (n = 10).
Outcomes No outcomes of interest were reported.
Notes Reasons for post-randomisation drop-out:
1. Colectomy for ulcerative colitis (1 participant in the treatment group).
2. Non-compliance (1 participant in the placebo group).
43Pharmacological interventions for primary sclerosing cholangitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Knox 1994 (Continued)
3. Finding of an unusual bile duct mass of unknown nature seen on protocol
endoscopic retrograde cholangiopancreatography (then diagnosed as
cholangiocarcinoma) (1 participant in the placebo group).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “The code was broken on patients who were judged
to be treatment failures”
Comment: Additional details were not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “A double-blind controlled trial of oral-pulse
methotrexate therapy in the treatment of primary sclerosing
cholangitis.…Methotrexate (or placebo) was administered
orally each week in three divided doses of 5 mg every 12
hours (15 mg/wk) for 2 years in a double-blind manner.
Identical methotrexate and placebo tablets were kindly pro-
vided by Lederle laboratories”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A double-blind controlled trial of oral-pulse
methotrexate therapy in the treatment of primary scleros-
ing cholangitis.Methotrexate (or placebo) was administered
orally each week in three divided doses of 5 mg every 12
hours (15 mg/wk) for 2 years in a double-blind manner.
Identical methotrexate and placebo tablets were kindly pro-
vided by Lederle laboratories”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias High risk Quote: “Identical methotrexate and placebo tablets were
kindly provided by Lederle laboratories..Supported byGen-
eral Research Center grant MOlRR00054 from the Na-
tional Institutes of Health and Lederle Laboratories, Pearl
River, New York”
Comment: The trial was funded by a party with vested
interest in the results
Other bias Low risk Comment: no other bias.
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LaRusso 1988
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 70.
Post-randomisation drop-outs: unclear.
Revised sample size: 70.
Mean age: 42 years.
Females: 26 (37.1%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on the following criteria:
i) Established liver disease for longer than 6 months.
ii) Serum level of alkaline phosphatase greater than 2 times the upper limit of
normal.
iii) Cholangiogram demonstrating diffuse (> 25%) narrowing, irregularity,
dilatation, and tortuosity of the extrahepatic biliary ductal system with or without
involvement of the intrahepatic ductal system.
iv) Pre-entry liver biopsy specimen compatible with the diagnosis of primary
sclerosing cholangitis and showing cholangitis or portal hepatitis (stage I); periportal
fibrosis or periportal hepatitis (stage II); septal fibrosis, bridging necrosis, or both (stage
III); or biliary cirrhosis (stage IV).
Exclusion criteria:
1. Previous biliary tract surgery (excluding simple cholecystectomy) or documented
choledocholithiasis (not cholelithiasis) before the diagnosis of primary sclerosing
cholangitis.
2. Radiographic changes strongly suggestive of cholangiocarcinoma.
3. Alcohol abuse.
4. Malignancy other than skin cancer.
Follow-up: 36 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: penicillamine 750 mg/d over the period of follow-up of the study (n = 39)
Group 2: placebo over the period of follow-up of the study (n = 31)
Outcomes 1. Mortality.
2. Number of any type of adverse events.
3. Number of severe adverse events.
4. Liver transplant.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We initiated in 1980 a randomized double-blind
trial of penicillamine versus placebo. Patients were ran-
domly assigned to drug or placebo groups. Randomization
was weighted in favour of the drug group in anticipation of
possible drug toxicity requiring severance from the study.
Penicillamine and placebo (furnished to us through the
courtesy of Merck Sharp & Dohme, West Point, Pa.) were
dispensed in identical yellow capsules by one pharmacist”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “We initiated in 1980 a randomized double-blind
trial of penicillamine versus placebo. Patients were ran-
domly assigned to drug or placebo groups. Randomization
was weighted in favour of the drug group in anticipation of
possible drug toxicity requiring severance from the study.
Penicillamine and placebo (furnished to us through the
courtesy of Merck Sharp & Dohme, West Point, Pa.) were
dispensed in identical yellow capsules by one pharmacist”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and liver transplantation were reported
For-profit bias High risk Quote: “This work was supported by the Mayo Founda-
tion, by a grant-in-aid from Merck Sharp & Dohme Re-
search Laboratories and in part by a grant from theNational
Institutes of Health (RR585)”
Comment: The trial was funded by a party with vested
interest in the results
Other bias Low risk Comment: no other bias.
Lindor 1997
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 105.
Post-randomisation drop-outs: 3 (2.9%).
Revised sample size: 102.
Mean age: 43 years.
Females: 44 (43.1%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on the following criteria:
i) Chronic cholestasis of at least 6 months’ duration.
ii) Alkaline phosphatase at least 1.5 times the upper limit of normal.
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iii) Retrograde, operative, or percutaneous cholangiographic findings of
intrahepatic or extrahepatic biliary duct obstruction, beading, or narrowing consistent
with primary sclerosing cholangitis.
iv) Liver biopsy with compatible findings in the previous 3 months.
Exclusion criteria:
1. Treatment with ursodiol, colchicine, corticosteroids, cyclosporine, methotrexate,
or penicillamine in the preceding 3 months.
2. Anticipated need of liver transplantation within 1 year (estimated 1-year survival
≤ 50% on the basis of the Mayo Risk score).
3. Recurrent variceal haemorrhage, spontaneous uncontrolled encephalopathy, or
ascites resistant to diuretics.
4. Age younger than 18 years or older than 70 years.
5. Features suggesting other liver disease or cholangiocarcinoma.
6. History of intraductal stones or biliary tract operations aside from
cholecystectomy.
7. Recurrent ascending cholangitis requiring hospitalisation more than 2 times a
year.
Follow-up: mean follow-up 27 months (minimum 3 months).
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose UDCA (13-15 mg/kg/d) over the period of follow-up of the study
(n = 51)
Group 2: identical-appearing placebo over the period of follow-up of the study (n = 51)
Outcomes Time to liver transplantation.
Notes Reasons for post-randomisation drop-out:
1. Missing follow-up beyond 3 months (2 participants in the UDCA group, 1
participant in the placebo group).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was carried out separately for
each of the eight strata (combination of variables) with a
computer generated, blocked, randomised drug/assignment
schedule.
Patient groups were stratified according to histologic stage,
serum bilirubin and the presence or absence of oesophageal
varices”
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The patients, physicians, nurses and study coor-
dinators were blinded as to whether active drug or placebo
was being administrated”
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The patients, physicians, nurses and study coor-
dinators were blinded as to whether active drug or placebo
was being administrated”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Supported in part by Axcan Pharma (produces
UDCA)”.
Comment: The trial was funded by a party with vested
interest in the results
Other bias Low risk Comment: no other bias.
Lindor 2009
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 150.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 150.
Mean age: 47 years.
Females: 64 (42.7%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on the following criteria:
i) Chronic cholestatic disease for at least 6 months.
ii) Serum alkaline phosphatase at least 1.5 times the upper limit of normal.
iii) Retrograde, operative, magnetic resonance, or percutaneous
cholangiography revealing intrahepatic and/or extrahepatic biliary duct obstruction,
beading, or narrowing within 1 year of study entry.
iv) Liver biopsy in the previous 1 year available for review and compatible with
primary sclerosing cholangitis (included fibrous cholangitis, ductopenia with periportal
inflammation, and biliary fibrosis).
Exclusion criteria:
1. Coexistent conditions such as preexisting advanced malignancy or severe
cardiopulmonary disease that would limit life expectancy to less than 2 years.
2. Inability to provide consent.
3. Treatment with UDCA, pentoxifylline, corticosteroids, cyclosporin, colchicine,
azathioprine, methotrexate, D-penicillamine, budesonide, nicotine, pirfenidone, or
tacrolimus in the 3 months before study entry.
4. Patients with inflammatory bowel disease requiring specific treatment in the
preceding 3 months (except mesalazine compound maintenance).
5. Anticipated need for liver transplantation within 2 years (expected survival at 2
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years < 80% according to the Mayo score).
6. Recurrent variceal bleeding, spontaneous uncontrolled encephalopathy, INR > 1.
5 uncorrected by vitamin K, resistant ascites (anticipating survival < 1 year).
7. Pregnancy or lactation.
8. Age younger than 18 years or older than 75 years.
9. Liver disease due to other causes.
10. Previous intraductal stones or biliary tree surgery other than cholecystectomy,
such as biliary drainage procedures, preceding the diagnosis of primary sclerosing
cholangitis.
11. Recurrent ascending cholangitis requiring hospitalisation (more than 2 times/y).
Follow-up: planned 60 months, but study stopped earlier owing to futility. Only 50
participants had a cholangiography at 60 months. Biochemical follow-up
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: high-dose UDCA (28-30 mg/kg/d) continued even after primary endpoint
was reached, except for liver transplantation or death (n = 76).
Group 2: identical placebo continued even after primary endpoint was reached, except
for liver transplantation or death (n = 74)
Outcomes 1. Mortality.
2. Cholangiocarcinoma.
3. Liver transplant.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-based dynamic allocation used to as-
sign patients to study groups via the coordinating centre in
Rochester, MN”
Allocation concealment (selection bias) Low risk Quote: “Computer-based dynamic allocation used to as-
sign patients to study groups via the coordinating centre in
Rochester, MN”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The physician, study coordinator, and patient were
blinded as to whether active drug or placebo was being
administered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The physician, study coordinator, and patient were
blinded as to whether active drug or placebo was being
administered”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All randomised participants were included in
the group to which they were allocated (i.e. intention-to-
treat analysis was performed)
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Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and liver transplantation were reported
For-profit bias High risk Quote: “Supported by National Institute of Diabetes and
Digestive and Kidney diseases Grant 56924 and Ax-
can Pharma (produces UDCA) as well as well as Grant
M01RR00065 from the National Center for Research re-
sources.”
Comment: The trial was funded by a party with vested
interest in the results
Other bias Low risk Comment: no other bias.
Lo 1992
Methods Randomised clinical trial.
Participants Country: UK.
Number randomised: 18.
Post-randomisation drop-outs: 4 (22.2%).
Revised sample size: 14.
Mean age: 47 years.
Females: 7 (38.9%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis with cholangiography and liver biopsy.
Exclusion criteria: not stated.
Follow-up: 24 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose UDCA (10 mg/kg/d) over the period of follow-up of the study (n =
7).
Group 2: placebo over the period of follow-up of the study (n = 7)
Outcomes No outcomes of interest were reported.
Notes Reasons for post-randomisation drop-out:
1. Colon cancer (UDCA group; 1 participant).
2. Clinical deterioration or self-withdrawal (placebo group; 3 participants).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
Mitchell 2001
Methods Randomised clinical trial.
Participants Country: UK/Germany.
Number randomised: 26.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 26.
Mean age: 52 years.
Females: 7 (26.9%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on standard clinical,
biochemical, histological, and radiological features.
2. Absence of evidence of secondary cholangitis, hepatobiliary malignancy, or viral,
metabolic, or autoimmune liver disease.
Exclusion criteria:
1. Age between 18 and 80 years.
2. Treatment with UCDA in the preceding year.
3. Previous bile duct surgery.
4. Dominant extrahepatic or hilar duct stricture.
5. Previous choledocholithiasis.
6. Recurrent ascending cholangitis.
7. Previous history of variceal haemorrhage.
8. Decompensated liver disease.
9. Cholangiocarcinoma.
10. Active inflammatory bowel disease.
11. Any features of a coexisting liver disease or overlap syndrome.
Follow-up: 24 months.
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Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: moderate-dose (20 mg/kg/d) UDCA over the period of follow-up of the study
(n = 13).
Group 2: identical-appearing placebo over the period of follow-up of the study (n = 13)
Outcomes No outcomes of interest were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “This preliminary study was designed as a double
blind, randomized trial comparing the efficacy and safety
of UDCA with that of placebo treatment….The placebo
was an identical-appearing capsule administered in the same
quantity and manner”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “This preliminary study was designed as a double
blind, randomized trial comparing the efficacy and safety
of UDCA with that of placebo treatment. . .The placebo
was an identical-appearing capsule administered in the same
quantity and manner”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote:“Patients who were lost to follow-up or died during
the study periodwere included in the final analysis, provided
that at least one set of follow-up data was available”
Comment: No post-randomisation drop-outs were re-
ported.
Selective reporting (reporting bias) High risk Comment: No published protocol was available; noout-
comes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
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Methods Randomised clinical trial.
Participants Country: Sweden.
Number randomised: 84.
Post-randomisation drop-outs: unclear.
Revised sample size: 84.
Mean age: 42 years.
Females: 28 (37.8%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on typical cholangiographic
appearance.
Exclusion criteria: not stated.
Follow-up: 36 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: colchicine 1 mg/d over the period of follow-up of the study (n = 44).
Group 2: placebo identical in appearance over the period of follow-up of the study (n =
40)
Outcomes 1. Mortality.
2. Liver transplant.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The randomization procedure was performed for
each center using the sealed envelope technique”
Comment: Further information on sealed envelope tech-
nique is not available
Allocation concealment (selection bias) Unclear risk Quote: “The randomization procedure was performed for
each center using the sealed envelope technique”
Comment: Further information on sealed envelope tech-
nique is not available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The results of a double-blind, randomized, con-
trolled study comparing colchicine with placebo for 36
months in 84 patients with PSC are reported. After giving
informed consent, the patients in each center were random-
ized to receive 1 mg colchicine daily or a placebo identical
in appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The results of a double-blind, randomized, con-
trolled study comparing colchicine with placebo for 36
months in 84 patients with PSC are reported. After giving
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informed consent, the patients in each center were random-
ized to receive 1 mg colchicine daily or a placebo identical
in appearance”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and liver transplant were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
Olsson 2005
Methods Randomised clinical trial.
Participants Country: Sweden/Norway.
Number randomised: 219.
Post-randomisation drop-outs: 21 (9.6%).
Revised sample size: 198.
Mean age: 43 years.
Females: 58 (29.3%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on cholangiography.
2. Age between 18 and 70 years.
3. Body weight lower than 115 kg.
4. Expected survival longer than 1 year.
Exclusion criteria:
1. Earlier treatment with UDCA.
2. Planned pregnancy within the forthcoming 5 years.
3. Alcohol abuse and other forms of abuse.
4. Hepatitis B or hepatitis C infection.
Follow-up: 60 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: moderate-dose UDCA (17-23 mg/kg/d) over the period of follow-up of the
study (n = 97).
Group 2: placebo (250 mg gelatin capsules containing microcrystalline cellulose, corn-
starch, and magnesium stearate) over the period of follow-up of the study (n = 101)
Outcomes 1. Mortality.
2. Proportion of participants with any type of adverse events.
3. Cholangiocarcinoma.
4. Liver transplant.
5. Quality of life.
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Notes Reasons for post-randomisation drop-out:
1. Participants who did not attended any follow-up visit.
2. Participants who never took capsules.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Low risk Quote: “The trial code was kept at the pharmacies in the
hospitals. The code was not broken until data from all pa-
tients had been collected”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We conducted a randomized, double-blind,
placebo controlled, multicenter….At that time we had re-
cruited 219 patients (121 from Sweden, 77 from Norway,
and 21 from Denmark) who were randomized to either
UDCA (in a daily dose of 17-23 mg/kg of body weight
divided in 2 doses) or placebo in identical 250-mg gelatin
capsules containing microcrystalline cellulose”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “We conducted a randomized, double-blind,
placebo controlled, multicenter….At that time we had re-
cruited 219 patients (121 from Sweden, 77 from Norway,
and 21 from Denmark) who were randomized to either
UDCA (in a daily dose of 17-23 mg/kg of body weight
divided in 2 doses) or placebo in identical 250-mg gelatin
capsules containing microcrystalline cellulose”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and liver transplant were reported
For-profit bias High risk Quote: “Supported by Dr Falk Pharma GmbH”.
Comment: The trial was funded by a party with vested
interest in the results (this company produces UDCA)
Other bias Low risk Comment: no other bias.
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Rahimpour 2016
Methods Randomised clinical trial.
Participants Country: Iran.
Number randomised: 29.
Post-randomisation drop-outs: 0 (0%).
Revised sample size: 29.
Average age: 36 years.
Females: 12 (41.4%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Age older than 18 years and younger than 66 years.
2. Diagnosed primary sclerosing cholangitis (chronic liver disease described by
advanced course of cholestasis, inflammation with intrahepatic and extrahepatic bile
duct fibrosis) with cholestasis longer than 3 months, magnetic resonance
cholangiopancreatography (MRCP), and pathological confirmation.
Exclusion criteria:
1. Symptoms of decompensated cirrhosis including ascites, hepatic encephalopathy,
and variceal bleeding.
2. Concomitant usage of corticosteroids, immunosuppressives, and other antibiotics
within 3 months before the study.
3. History of allergy to vancomycin.
4. Considered as on the waiting list for liver transplantation.
5. Renal failure with creatinine higher than 1.5 mg/dL.
6. Thrombocytopenia.
7. Different or concomitant cause of liver disease other than primary sclerosing
cholangitis.
8. Pregnancy and lactation.
9. Drug or alcohol abuse.
Follow-up: 12 weeks after 12 weeks of treatment.
Interventions Participants were randomly assigned to 2 groups.
Group 1: vancomycin 125 mg QDS (n = 18).
Group 2: placebo (n = 11).
Outcomes 1. Mortality.
2. Adverse events.
3. Malignancy.
4. Liver cirrhosis.
5. Decompensated liver disease.
6. Liver transplantation.
Notes Trial authors provided additional information on outcomes in February 2017
Risk of bias
Bias Authors’ judgement Support for judgement
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Rahimpour 2016 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “An independent investigator who was blinded to
the treatment groupmade random allocation cards by using
computer-generated random numbers”
Allocation concealment (selection bias) Low risk Quote: “Another investigator who was also blinded was
responsible for the patients’ enrolments and data collection”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We used the triple blinding method which meant
that patients, investigators who were responsible for the
patients’ enrolment and the analyzer of the data at the end
of the study were unaware of identities to reduce the chance
of bias occurrence in the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “We used the triple blinding method which meant
that patients, investigators who were responsible for the
patients’ enrolment and the analyzer of the data at the end
of the study were unaware of identities to reduce the chance
of bias occurrence in the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: No post-randomisation drop-outs were re-
ported.
Selective reporting (reporting bias) Low risk Comment: No published protocol was available; mortality
and morbidity were reported
For-profit bias Low risk Quote: “This study was supported by a grant from the
Tehran University of Medical Sciences”
Other bias Low risk Comment: no other bias.
Rasmussen 1998
Methods Cross-over randomised clinical trial.
Participants Country: Denmark.
Number randomised: 13.
Post-randomisation drop-outs: not stated.
Revised sample size: 13.
Mean age: not stated.
Females: not stated.
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis.
2. Raised alkaline phosphatase.
3. Symptoms such as pruritus, pain, jaundice.
Exclusion criteria: not stated.
Follow-up: 24 months.
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Rasmussen 1998 (Continued)
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: methotrexate (10 mg/m2 body area/wk) for the first year followed by placebo
(n = 5).
Group 2: placebo followed by methotrexate (10 mg/m2 body area/wk) (n = 8).
Outcomes No outcomes of interest were reported before cross-over.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Trial authors stated double-blind and
have used placebo. However, the groups blinded
were not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Trial authors stated double-blind and
have used placebo. However, the groups blinded
were not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (reporting bias) High risk Comment: No published protocol was available;
no outcomes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
Sandborn 1993
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 35.
Post-randomisation drop-outs: 9 (25.7%).
Revised sample size: 26.
Mean age: 39 years.
Females: 10 (38.5%).
Separate data for the subgroup with ulcerative colitis: yes.
Inclusion criteria:
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1. Histological and cholangiographic findings consistent with primary sclerosing
cholangitis.
2. Cholestatic biochemical abnormalities for at least 6 months.
3. Serum alkaline phosphatase at least 2 times the upper limit of normal.
4. Diagnosis of ulcerative colitis (participants selected after randomisation).
Exclusion criteria:
1. Presence of oesophageal varices.
2. Ultrasonographic or peritoneoscopic evidence of ascites.
3. Features of liver cirrhosis at biopsy.
4. Serum creatinine higher than 141 nmol/L or rate of iothalamate clearance lower
than 60 mL/min.
5. Uncontrolled hypertension (systolic arterial pressure > 160 mm Hg, diastolic
arterial pressure > 95 mm Hg).
6. History of neoplastic disease other than skin cancer.
7. Previous immunosuppressive therapy (prednisolone, azathioprine, chlorambucil).
8. Coexistence of other liver disease documented at liver biopsy.
Follow-up: final analysis performed after mean follow-up of 34 months in the placebo
group and 36 months in the cyclosporin group
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose cyclosporin (initial dose 5 mg/kg/d) for at least 1 year (mean 2.8
years) (n = 16).
Group 2: placebo for at least 1 year (mean 3 years) (n = 10)
Outcomes 1. Numbers of any types of adverse events.
2. Cholangiocarcinoma.
Notes Reasons for post-randomisation drop-out:
1. Previous colectomy for ulcerative colitis (2 participants in the cyclosporine group
and 1 participant in the placebo group).
2. Treatment discontinuation (1 participant in the cyclosporine group).
3. Non-diagnosis of ulcerative colitis (5 participants).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “From 27 June 1985 to 13 July 1988, 35 patients
with precirrhotic primary sclerosing cholangitis were ran-
domly allocated to receive low dose cyclosporin (initial dose
5 mg/kg/day) or placebo in a double blind trial”
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Sandborn 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “From 27 June 1985 to 13 July 1988, 35 patients
with precirrhotic primary sclerosing cholangitis were ran-
domly allocated to receive low dose cyclosporin (initial dose
5 mg/kg/day) or placebo in a double blind trial”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs were reported.
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Supported by grants from the Sandoz Corporation
and the Mayo Foundation”
Comment: The trial was funded by parties with vested in-
terest in the results
Other bias Low risk Comment: no other bias.
Sterling 2004
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 25.
Post-randomisation drop-outs: 9 (36%).
Revised sample size: 16.
Mean age: 44 years.
Females: 10 (62.5%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis made by endoscopic retrograde
cholangiopancreatography, magnetic resonance cholangiopancreatography, or liver
biopsy.
Exclusion criteria:
1. Evidence of secondary cholangitis.
2. Chronic viral hepatitis (B or C), autoimmune or other metabolic liver conditions.
3. Hepatobiliary malignancy.
4. History of cholangitis within 3 months of study entry.
5. Use of steroids or azathioprine within the preceding 3 months.
6. History of liver decompensation (variceal bleeding, ascites, prolongation of
prothrombin time > 2 seconds, or hepatic encephalopathy).
Follow-up: 24 months.
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: mycophenolate mofetil 1000 mg twice/d and low-dose UDCA (13-15 mg/kg/
d) combined treatment over the period of follow-up of the study (n = 6).
Group 2: low-dose UDCA (13-15 mg/kg/d) over the period of follow-up of the study
(n = 10)
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Sterling 2004 (Continued)
Outcomes No outcomes of interest were reported.
Notes Reasons for post-randomisation drop-out:
1. One participant in each group withdrew consent.
2. One participant in the UDCA group moved away from the area.
3. Two participants in the combination group discontinued the study drug for
personal reasons unrelated to side effects.
4. One participant in the combination group had recurrence of chronic sinusitis.
5. Two participants in the combination group and 1 in the UDCA alone group had
progression of their liver disease and subsequent referral for liver transplantation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Low risk Quote: “Concealed randomisation via investigational phar-
macy or by concealed envelopes” (study author’s reply)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither patient nor investigator was blinded to
study medication”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Neither patient nor investigator was blinded to
study medication”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “All data were analysed by the intention-to-treat
method”
Comment: Post-randomisation drop-outs were reported.
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias High risk Quote: “Supported in part by a NIH grant to the Gen-
eral Clinical Research Center of Virginia Commonwealth
University Medical Center, M01-RR-00065-35 and by the
generous support of Roche Laboratory, Nutley, NJ and Ax-
can Scandipharm, Birmingham, AL, USA”
Comment: The trial was fundedby a partywith vested inter-
est in the results (Roche produces mycophenolate mofetil)
Other bias Low risk Comment: no other bias.
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Stiehl 1989
Methods Randomised clinical trial.
Participants Country: Germany.
Number randomised: 16.
Post-randomisation drop-outs: 4 (25%).
Revised sample size: 12.
Mean age: data not available.
Females: data not available.
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria: not stated.
Exclusion criteria: not stated.
Follow-up: unclear: definitive analysis planned for 12 months and interim analysis at 3
months
Interventions Participants were randomly assigned to 1 of 2 groups.
Group 1: low-dose UDCA (8-10 mg/kg/d) over the period of follow-up of the study (n
= 6).
Group 2: placebo over the period of follow-up of the study (n = 6)
Outcomes No outcomes of interest were reported.
Notes Reasons for post randomisation drop-out not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: This information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: This information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; no out-
comes of interest were reported
For-profit bias Unclear risk Comment: This information was not available.
Other bias Low risk Comment: no other bias.
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Tabibian 2013
Methods Randomised clinical trial.
Participants Country: USA.
Number randomised: 35.
Post-randomisation drop-outs: 7 (20%).
Revised sample size: 28.
Mean age: 40 years.
Females: 14 (40%).
Separate data for the subgroup with ulcerative colitis: no.
Inclusion criteria:
1. Diagnosis of primary sclerosing cholangitis based on serum alkaline phosphatase
at least 1.5 times the upper limit of normal for at least 6 months and cholangiography
demonstrating intrahepatic and/or extrahepatic biliary strictures, beading, or
irregularity consistent with primary sclerosing cholangitis.
Exclusion criteria:
1. Treatment with any investigational agents, such as UDCA or other antibiotics,
within 3 months of the study.
2. Prior history of allergic reactions to vancomycin and/or metronidazole.
3. Evidence of decompensated liver disease such as recurrent variceal bleeding,
refractory ascites, or spontaneous hepatic encephalopathy.
4. Anticipated need for liver transplant within 1 year as determined by Mayo
Primary Sclerosing Cholangitis risk score.
5. Findings highly suggestive of liver disease of an alternative or concomitant
aetiology, such as chronic alcoholic liver disease, chronic hepatitis B or C infection,
haemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, non-alcoholic
steatohepatitis, primary biliary cirrhosis, or secondary sclerosing cholangitis.
6. Pregnancy or lactation.
7. Active illicit drug or alcohol abuse.
8. Age younger than 18 years or older than 75 years.
9. UDCA treatment in the previous 3 months.
Follow-up: 3 months.
Interventions Participants were randomly assigned to 1 of 4 groups.
Group 1: vancomycin 125 or 250 mg orally 4 times a day for 12 weeks (n = 15)
Group 2: metronidazole 250 or 500 mg orally 3 times a day for 12 weeks (n = 13)
Outcomes Numbers of any types of adverse events.
Notes Reasons for post-randomisation drop-out:
1. One participant stopped treatment indefinitely owing to migraine headaches and
increased diarrhoea (low-dose vancomycin group).
2. One participant stopped treatment indefinitely owing to diarrhoea and increased
fatigue (high-dose vancomycin group).
3. One participant stopped treatment indefinitely owing to persistent dyspepsia
(low-dose metronidazole group).
4. One participant was severed because of non-compliance (low-dose metronidazole
group).
5. One participant stopped treatment indefinitely owing to nausea and flu (high-
dose metronidazole group).
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Tabibian 2013 (Continued)
6. One participant stopped treatment indefinitely owing to dyspepsia and burning
in the eyes (high-dose metronidazole group).
7. One participant stopped treatment indefinitely owing to dyspepsia, diarrhoea,
and anorexia (high-dose metronidazole group).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Drugs were packaged in identical gelatin capsules,
and patients and investigators were blinded to the type and
dose of the drug”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Drugs were packaged in identical gelatin capsules,
and patients and investigators were blinded to the type and
dose of the drug”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: Post-randomisation drop-outs may be related to
the treatment that participants received
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias Low risk Quote: “Funded by the PSC Partners Seeking a Cure 2009-
2010 Research Grant”
Other bias Low risk Comment: no other bias.
Trauner 2016
Methods Randomised clinical trial.
Participants Country: international, multi-centric.
Number randomised: 159.
Post-randomisation drop-outs: not stated.
Revised sample size: 159.
Average age: not stated
Females: not stated
Inclusion criteria:
1. Patients with primary sclerosing cholangitis and elevated alkaline phosphatase.
Follow-up: 4 weeks after 12 weeks of treatment.
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Interventions Participants were randomly assigned to 4 groups.
Group 1: 3 randomised doses of norursodeoxycholic acid (500 mg/d, 1000 mg/d, and
1500 mg/d) (n = not stated).
Group 2: placebo (n = not stated).
Outcomes 1. Serious adverse events.
Notes Given that the number of participants in each group was not reported, it was not possible
to include this trial in the analysis. The proportion of serious adverse events was not
reported so that we could report this information in a narrative manner
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: This information was not available.
Allocation concealment (selection bias) Unclear risk Comment: This information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: Placebo was used, but blinding was not men-
tioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Placebo was used, but blinding was not men-
tioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: This information was not available.
Selective reporting (reporting bias) High risk Comment: No published protocol was available; mortality
was not reported
For-profit bias High risk Quote: “Employment: Dr. Falk Pharma GmbH”.
Comment: Two of the co-authors were employed by the
company that manufactures the drug
Other bias Low risk Comment: no other bias.
AMA = antimitochondrial antibody; PSC = primary sclerosing cholangitis; UDCA = ursodeoxycholic acid
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beuers 1998 Not a RCT (comments on Lindor 1997).
Chapman 2005 Not a RCT.
Chapman 2009 Editorial on Lindor 2009.
Eisenburg 1997 Not an RCT.
Fromm 1992 Comment on a non-RCT.
Goldberg 1992 Comment on a non-RCT.
Gross 1993 Comment on a non-RCT.
Harnois 2001 Not a RCT.
Hay 2001 The study includes transplanted patients.
Imam 2011 Not an RCT.
Kuiper 2010 No separate data for participants with primary sclerosing cholangitis
Kurihara 2003 Not a RCT.
Lankarani 2003 Not a RCT.
Lankarani 2005 Comment on an included trial (Sterling 2004).
Lindor 1995 Not an RCT.
Lindor 2005 Not a RCT.
Lindor 2009a Review, not a RCT.
Mayo 2007 No separate data for participants with primary sclerosing cholangitis
Silveira 2008 Not a RCT.
Spengler 1993 Comments on Beuers 1992 and other published experiences.
Stiehl 1989a Not a RCT.
Stiehl 1989b Not a RCT.
Stiehl 1994 Not a RCT.
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Stiehl 1994a All participants received the same treatment (UDCA) for 1 year before the randomised period (UDCA and
placebo groups)
Stiehl 1996 Review, not a RCT.
Tabibian 1989 Not a RCT.
Tada 2006 Not a RCT.
Ter Borg 2004 No separate data for participants with primary sclerosing cholangitis
Triantos 2012 Comment on an excluded study (Imam 2011).
van de Meeberg 1996 No separate data for participants with primary sclerosing cholangitis
van Hoogstraten 1998 No comparison between different treatments: Participants in both arms received the same dose of UDCA
once a day or in divided doses
van Hoogstraten 2000 In this RCT, participants received different types and doses of steroids in combination with UDCA
Van Thiel 1992 Control group received colchicine or no treatment, and no separate data were available for participants who
received no treatment
Villamil 2005 No separate data for participants with primary sclerosing cholangitis
Vleggaar 2001 Treatment was not targeted at improving outcomes related to primary sclerosing cholangitis
Vleggaar 2008 No pharmacological agents were studied.
Wagner 1971 Not a RCT.
RCT = randomised clinical trial; UDCA = ursodeoxycholic acid
Characteristics of studies awaiting assessment [ordered by study ID]
Anonymous 2006
Methods Awaiting full text.
Participants
Interventions
Outcomes
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Anonymous 2006 (Continued)
Notes
ISRCTN16531030
Methods Randomised, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Trial of low-dose, medium-dose, and high-dose ursodeoxycholic acid with placebo in primary sclerosing cholangitis
Outcomes Not available.
Notes Recruitment status: completed.
NCT00059202
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions High-dose UDCA (28-30 mg/kg/d) vs placebo.
Outcomes Cirrhosis, decompensated cirrhosis, cholangiocarcinoma, liver transplantation, quality of life, and mortality
Notes Recruitment status: completed.
UDCA = ursodeoxycholic acid
Characteristics of ongoing studies [ordered by study ID]
EUCTR2012-004170-26-IT
Trial name or title EUCTR2012-004170-26-IT.
Methods Randomised double-blinded placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions N-acetylcysteine 600 mg vs placebo.
Outcomes Quality of life.
Starting date Not stated.
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EUCTR2012-004170-26-IT (Continued)
Contact information agasbarrini@RM.UNICATT.IT
Notes Not recruiting.
EUCTR2015-003310-24-SE
Trial name or title UDCAPSCSURV.
Methods Phase 3, open-label, randomised, prospective clinical trial.
Participants Patients with primary sclerosing cholangitis.
Interventions 17-23 mg/kg/d UDCA vs placebo.
Outcomes Decompensated liver cirrhosis and liver transplantation.
Starting date Not stated.
Contact information hanns-ulrich.marschall@gu.se
Notes
EUCTR2015-003392-30-GB
Trial name or title EUCTR2015-003392-30-GB.
Methods Phase 2, randomised, double-blind, placebo-controlled, parallel-group, multiple-centre study
Participants Patients with primary sclerosing cholangitis.
Interventions NGM282 vs placebo.
Outcomes No outcomes of interest for this review.
Starting date Not stated.
Contact information clinical@ngmbio.com
Notes
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NCT01672853
Trial name or title NCT01672853.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions GS-6624, a monoclonal antibody against Lysyl Oxidase Like 2 (LOXL2), vs placebo
Outcomes Adverse events.
Starting date February 2013.
Contact information Rob Myers, M.D. Gilead Sciences.
Notes
NCT01688024
Trial name or title NCT01688024.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Mitomycin C vs placebo.
Outcomes Adverse events.
Starting date September 2012.
Contact information chen37@jhmi.edu
Notes
NCT01755507
Trial name or title NCT01755507.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Norursodeoxycholic acid vs placebo.
Outcomes Adverse events.
Starting date December 2012.
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NCT01755507 (Continued)
Contact information roels@drfalkpharma.de
Notes
NCT02177136
Trial name or title NCT02177136.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Obeticholic acid vs placebo.
Outcomes Adverse events.
Starting date December 2014.
Contact information kate.mckeown@interceptpharma.com
Notes
NCT02704364
Trial name or title NCT02704364.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions NGM282 vs placebo.
Outcomes No outcomes of interest for this review.
Starting date February 2016.
Contact information kkim@ngmbio.com
Notes
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NCT02943460
Trial name or title NCT02943460.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions GS-9674 vs placebo.
Outcomes Adverse events.
Starting date November 2016.
Contact information GS-US-428-4025@Gilead.com
Notes
NCT03035058
Trial name or title NCT03035058.
Methods Randomised, double-blind, placebo-controlled trial.
Participants Patients with primary sclerosing cholangitis.
Interventions Vedolizumab vs placebo.
Outcomes No outcomes of interest for this review.
Starting date February 2017.
Contact information medicalinformation@tpna.com
Notes
vs = versus
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic
acid dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Colchicine vs placebo 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.04, 5.07]
1.2 Penicillamine vs placebo 1 70 Odds Ratio (M-H, Fixed, 95% CI) 1.18 [0.39, 3.58]
1.3 Steroids vs placebo 1 11 Odds Ratio (M-H, Fixed, 95% CI) 3.0 [0.10, 90.96]
1.4 Ursodeoxycholic acid vs
placebo
2 348 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.63, 3.63]
1.5 Vancomycin vs placebo 1 29 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events proportion 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Infliximab vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events number 3 rate ratio (Fixed, 95% CI) Totals not selected
3.1 Infliximab vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Penicillamine vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Steroids vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events proportion 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Ursodeoxycholic acid vs
placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events number 5 rate ratio (Fixed, 95% CI) Totals not selected
5.1 Cyclosporin vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Penicillamine vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Steroids vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Ursodeoxycholic acid
plus metronidazole vs
ursodeoxycholic acid
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Vancomycin vs
metronidazole
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Quality of life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Ursodeoxycholic acid vs
placebo
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Liver transplantation 7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Colchicine vs placebo 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.59 [0.09, 3.71]
7.2 Penicillamine vs placebo 1 70 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.32, 4.01]
7.3 Steroids vs placebo 1 11 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Ursodeoxycholic acid vs
placebo
2 348 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.52, 1.81]
7.5 Vancomycin vs placebo 1 29 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Ursodeoxycholic acid
plus metronidazole vs
ursodeoxycholic acid
1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.03, 2.90]
73Pharmacological interventions for primary sclerosing cholangitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8 Cholangiocarcinoma 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Cyclosporin vs placebo 1 26 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 5.20]
8.2 Ursodeoxycholic acid vs
placebo
2 348 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.48, 3.68]
8.3 Vancomycin vs placebo 1 29 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid
dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality at maximal follow-up 6 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Colchicine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Penicillamine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Ursodeoxycholic acid
(high) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Ursodeoxycholic acid
(moderate) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events proportion 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Infliximab vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Serious adverse events number 4 rate ratio (Fixed, 95% CI) Totals not selected
3.1 Infliximab vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Penicillamine vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Steroids vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(moderate)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(low)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Ursodeoxycholic acid
(moderate) vs ursodeoxycholic
acid (low)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events proportion 3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Ursodeoxycholic acid
(moderate) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events number 6 rate ratio (Fixed, 95% CI) Totals not selected
5.1 Cyclosporin vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Penicillamine vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Steroids vs placebo 1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.4 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(low)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(moderate)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Ursodeoxycholic acid
(low) plus metronidazole vs
ursodeoxycholic acid (low)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Ursodeoxycholic acid
(moderate) vs ursodeoxycholic
acid (low)
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Vancomycin vs
metronidazole
1 rate ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Quality of life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Ursodeoxycholic acid
(moderate) vs placebo
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Liver transplantation 8 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Colchicine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Penicillamine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Steroids vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Ursodeoxycholic acid
(high) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 Ursodeoxycholic acid
(moderate) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 Ursodeoxycholic acid
(moderate) vs ursodeoxycholic
acid (low)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.8 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(low)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 Ursodeoxycholic acid
(high) vs ursodeoxycholic acid
(moderate)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.10 Ursodeoxycholic acid
(low) plus metronidazole vs
ursodeoxycholic acid (low)
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Cholangiocarcinoma 4 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Cyclosporin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Ursodeoxycholic acid
(high) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Ursodeoxycholic acid
(moderate) vs placebo
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.4 Vancomycin vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 1 Mortality at maximal follow-up.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 1 Mortality at maximal follow-up
Study or subgroup Intervention Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Colchicine vs placebo
Olsson 1995 1/44 2/40 100.0 % 0.44 [ 0.04, 5.07 ]
Subtotal (95% CI) 44 40 100.0 % 0.44 [ 0.04, 5.07 ]
Total events: 1 (Intervention), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Penicillamine vs placebo
LaRusso 1988 10/39 7/31 100.0 % 1.18 [ 0.39, 3.58 ]
Subtotal (95% CI) 39 31 100.0 % 1.18 [ 0.39, 3.58 ]
Total events: 10 (Intervention), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
3 Steroids vs placebo
Allison 1986 1/6 0/5 100.0 % 3.00 [ 0.10, 90.96 ]
Subtotal (95% CI) 6 5 100.0 % 3.00 [ 0.10, 90.96 ]
Total events: 1 (Intervention), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
4 Ursodeoxycholic acid vs placebo
Lindor 2009 5/76 3/74 34.5 % 1.67 [ 0.38, 7.24 ]
Olsson 2005 8/97 6/101 65.5 % 1.42 [ 0.48, 4.26 ]
Subtotal (95% CI) 173 175 100.0 % 1.51 [ 0.63, 3.63 ]
Total events: 13 (Intervention), 9 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
5 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
Subtotal (95% CI) 18 11 Not estimable
Total events: 0 (Intervention), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.12, df = 3 (P = 0.77), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours placebo
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Analysis 1.2. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 2 Serious adverse events proportion.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 2 Serious adverse events proportion
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infliximab vs placebo
Hommes 2008 0/4 0/3 Not estimable
2 Steroids vs placebo
Allison 1986 5/6 1/5 20.00 [ 0.93, 429.90 ]
3 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours placebo
Analysis 1.3. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 3 Serious adverse events number.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 3 Serious adverse events number
Study or subgroup Intervention Placebo log [rate ratio] rate ratio rate ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Infliximab vs placebo
Hommes 2008 4 3 -0.22 (2) 0.80 [ 0.02, 40.44 ]
2 Penicillamine vs placebo
LaRusso 1988 39 31 2.61 (1.46) 13.60 [ 0.78, 237.83 ]
3 Steroids vs placebo
Allison 1986 6 5 1.2 (0.79) 3.32 [ 0.71, 15.62 ]
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours placebo
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Analysis 1.4. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 4 Adverse events proportion.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 4 Adverse events proportion
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Steroids vs placebo
Allison 1986 5/6 1/5 20.00 [ 0.93, 429.90 ]
2 Ursodeoxycholic acid vs placebo
Olsson 2005 37/97 34/101 1.22 [ 0.68, 2.17 ]
3 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours placebo
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Analysis 1.5. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 5 Adverse events number.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 5 Adverse events number
Study or subgroup Intervention Control log [rate ratio] rate ratio rate ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cyclosporin vs placebo
Sandborn 1993 16 10 0.97 (0.5) 2.64 [ 0.99, 7.03 ]
2 Penicillamine vs placebo
LaRusso 1988 39 31 0.91 (0.38) 2.48 [ 1.18, 5.23 ]
3 Steroids vs placebo
Allison 1986 6 5 1.2 (0.79) 3.32 [ 0.71, 15.62 ]
4 Ursodeoxycholic acid plus metronidazole vs ursodeoxycholic acid
Farkkila 2004 37 34 0.86 (0.45) 2.36 [ 0.98, 5.71 ]
5 Vancomycin vs metronidazole
Tabibian 2013 16 13 -0.9 (0.39) 0.41 [ 0.19, 0.87 ]
0.005 0.1 1 10 200
Favours intervention Favours control
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Analysis 1.6. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 6 Quality of life.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 6 Quality of life
Study or subgroup Intervention Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ursodeoxycholic acid vs placebo
Olsson 2005 97 62.4 (25.8) 101 61.1 (23.7) 1.30 [ -5.61, 8.21 ]
-10 -5 0 5 10
Favours placebo Favours intervention
Analysis 1.7. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 7 Liver transplantation.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 7 Liver transplantation
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Colchicine vs placebo
Olsson 1995 2/44 3/40 100.0 % 0.59 [ 0.09, 3.71 ]
Subtotal (95% CI) 44 40 100.0 % 0.59 [ 0.09, 3.71 ]
Total events: 2 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Penicillamine vs placebo
LaRusso 1988 7/39 5/31 100.0 % 1.14 [ 0.32, 4.01 ]
Subtotal (95% CI) 39 31 100.0 % 1.14 [ 0.32, 4.01 ]
Total events: 7 (Intervention), 5 (Control)
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
3 Steroids vs placebo
Allison 1986 0/6 0/5 Not estimable
Subtotal (95% CI) 6 5 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Ursodeoxycholic acid vs placebo
Lindor 2009 11/76 5/74 21.7 % 2.34 [ 0.77, 7.09 ]
Olsson 2005 11/97 18/101 78.3 % 0.59 [ 0.26, 1.32 ]
Subtotal (95% CI) 173 175 100.0 % 0.97 [ 0.52, 1.81 ]
Total events: 22 (Intervention), 23 (Control)
Heterogeneity: Chi2 = 3.86, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.10 (P = 0.92)
5 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
Subtotal (95% CI) 18 11 Not estimable
Total events: 0 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Ursodeoxycholic acid plus metronidazole vs ursodeoxycholic acid
Farkkila 2004 1/37 3/34 100.0 % 0.29 [ 0.03, 2.90 ]
Subtotal (95% CI) 37 34 100.0 % 0.29 [ 0.03, 2.90 ]
Total events: 1 (Intervention), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 1.33, df = 3 (P = 0.72), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours control
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Analysis 1.8. Comparison 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by
ursodeoxycholic acid dose, Outcome 8 Cholangiocarcinoma.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 1 Pharmacological treatments for primary sclerosing cholangitis: not stratified by ursodeoxycholic acid dose
Outcome: 8 Cholangiocarcinoma
Study or subgroup Intervention Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cyclosporin vs placebo
Sandborn 1993 0/16 1/10 100.0 % 0.19 [ 0.01, 5.20 ]
Subtotal (95% CI) 16 10 100.0 % 0.19 [ 0.01, 5.20 ]
Total events: 0 (Intervention), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 Ursodeoxycholic acid vs placebo
Lindor 2009 2/76 2/74 30.3 % 0.97 [ 0.13, 7.09 ]
Olsson 2005 7/97 5/101 69.7 % 1.49 [ 0.46, 4.88 ]
Subtotal (95% CI) 173 175 100.0 % 1.34 [ 0.48, 3.68 ]
Total events: 9 (Intervention), 7 (Placebo)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
3 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
Subtotal (95% CI) 18 11 Not estimable
Total events: 0 (Intervention), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =18%
0.002 0.1 1 10 500
Favours intervention Favours placebo
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Analysis 2.1. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 1 Mortality at maximal follow-up.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 1 Mortality at maximal follow-up
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Colchicine vs placebo
Olsson 1995 1/44 2/40 0.44 [ 0.04, 5.07 ]
2 Penicillamine vs placebo
LaRusso 1988 10/39 7/31 1.18 [ 0.39, 3.58 ]
3 Steroids vs placebo
Allison 1986 1/6 0/5 3.00 [ 0.10, 90.96 ]
4 Ursodeoxycholic acid (high) vs placebo
Lindor 2009 5/76 3/74 1.67 [ 0.38, 7.24 ]
5 Ursodeoxycholic acid (moderate) vs placebo
Olsson 2005 8/97 6/101 1.42 [ 0.48, 4.26 ]
6 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.01 0.1 1 10 100
Favours intervention Favours placebo
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Analysis 2.2. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 2 Serious adverse events proportion.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 2 Serious adverse events proportion
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infliximab vs placebo
Hommes 2008 0/4 0/3 Not estimable
2 Steroids vs placebo
Allison 1986 5/6 1/5 20.00 [ 0.93, 429.90 ]
3 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.005 0.1 1 10 200
Favours intervention Favours placebo
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Analysis 2.3. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 3 Serious adverse events number.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 3 Serious adverse events number
Study or subgroup Intervention Placebo log [rate ratio] rate ratio rate ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Infliximab vs placebo
Hommes 2008 4 3 -0.22 (2) 0.80 [ 0.02, 40.44 ]
2 Penicillamine vs placebo
LaRusso 1988 39 31 2.61 (1.46) 13.60 [ 0.78, 237.83 ]
3 Steroids vs placebo
Allison 1986 6 5 1.2 (0.79) 3.32 [ 0.71, 15.62 ]
4 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate)
Cullen 2008 9 11 0.2 (1) 1.22 [ 0.17, 8.67 ]
5 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low)
Cullen 2008 9 11 0.89 (1.22) 2.44 [ 0.22, 26.61 ]
6 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low)
Cullen 2008 11 11 0.69 (1.22) 1.99 [ 0.18, 21.78 ]
0.005 0.1 1 10 200
Favours intervention Favours placebo
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Analysis 2.4. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 4 Adverse events proportion.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 4 Adverse events proportion
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Steroids vs placebo
Allison 1986 5/6 1/5 20.00 [ 0.93, 429.90 ]
2 Ursodeoxycholic acid (moderate) vs placebo
Olsson 2005 0/4 0/3 Not estimable
3 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.001 0.01 0.1 1 10 100 1000
Favours intervention Favours placebo
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Analysis 2.5. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 5 Adverse events number.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 5 Adverse events number
Study or subgroup Intervention Control log [rate ratio] rate ratio rate ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cyclosporin vs placebo
Sandborn 1993 16 10 0.97 (0.5) 2.64 [ 0.99, 7.03 ]
2 Penicillamine vs placebo
LaRusso 1988 39 31 0.91 (0.38) 2.48 [ 1.18, 5.23 ]
3 Steroids vs placebo
Allison 1986 6 5 1.2 (0.79) 3.32 [ 0.71, 15.62 ]
4 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low)
Cullen 2008 9 11 0.2 (0.82) 1.22 [ 0.24, 6.09 ]
5 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate)
Cullen 2008 9 11 -0.09 (0.76) 0.91 [ 0.21, 4.05 ]
6 Ursodeoxycholic acid (low) plus metronidazole vs ursodeoxycholic acid (low)
Farkkila 2004 37 34 0.86 (0.45) 2.36 [ 0.98, 5.71 ]
7 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low)
Cullen 2008 11 11 0.29 (0.76) 1.34 [ 0.30, 5.93 ]
8 Vancomycin vs metronidazole
Tabibian 2013 16 13 -0.9 (0.39) 0.41 [ 0.19, 0.87 ]
0.005 0.1 1 10 200
Favours intervention Favours control
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Analysis 2.6. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 6 Quality of life.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 6 Quality of life
Study or subgroup Intervention Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ursodeoxycholic acid (moderate) vs placebo
Olsson 2005 97 62.4 (25.8) 101 61.1 (23.7) 1.30 [ -5.61, 8.21 ]
-10 -5 0 5 10
Favours placebo Favours intervention
Analysis 2.7. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 7 Liver transplantation.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 7 Liver transplantation
Study or subgroup Intervention Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Colchicine vs placebo
Olsson 1995 11/44 3/40 4.11 [ 1.06, 16.02 ]
2 Penicillamine vs placebo
LaRusso 1988 7/39 5/31 1.14 [ 0.32, 4.01 ]
3 Steroids vs placebo
Allison 1986 0/7 0/6 Not estimable
4 Ursodeoxycholic acid (high) vs placebo
Lindor 2009 11/76 5/74 2.34 [ 0.77, 7.09 ]
5 Ursodeoxycholic acid (moderate) vs placebo
0.01 0.1 1 10 100
Favours intervention Favours control
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(. . . Continued)
Study or subgroup Intervention Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Olsson 2005 11/97 18/101 0.59 [ 0.26, 1.32 ]
6 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
7 Ursodeoxycholic acid (moderate) vs ursodeoxycholic acid (low)
Cullen 2008 0/11 1/11 0.30 [ 0.01, 8.32 ]
8 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (low)
Cullen 2008 0/9 1/11 0.37 [ 0.01, 10.18 ]
9 Ursodeoxycholic acid (high) vs ursodeoxycholic acid (moderate)
Cullen 2008 0/9 0/11 Not estimable
10 Ursodeoxycholic acid (low) plus metronidazole vs ursodeoxycholic acid (low)
Farkkila 2004 1/37 3/34 0.29 [ 0.03, 2.90 ]
0.01 0.1 1 10 100
Favours intervention Favours control
Analysis 2.8. Comparison 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by
ursodeoxycholic acid dose, Outcome 8 Cholangiocarcinoma.
Review: Pharmacological interventions for primary sclerosing cholangitis
Comparison: 2 Pharmacological treatments for primary sclerosing cholangitis: stratified by ursodeoxycholic acid dose
Outcome: 8 Cholangiocarcinoma
Study or subgroup Intervention Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cyclosporin vs placebo
Sandborn 1993 0/16 1/10 0.19 [ 0.01, 5.20 ]
2 Ursodeoxycholic acid (high) vs placebo
Lindor 2009 2/76 2/74 0.97 [ 0.13, 7.09 ]
3 Ursodeoxycholic acid (moderate) vs placebo
Olsson 2005 7/97 5/101 1.49 [ 0.46, 4.88 ]
4 Vancomycin vs placebo
Rahimpour 2016 0/18 0/11 Not estimable
0.005 0.1 1 10 200
Favours intervention Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Characteristics table (according to comparisons)
Study
name
Number
of people
in inter-
vention
group
Number
of
people in
control
group
Risk of bias Over-
all risk of
bias
Random
sequence
genera-
tion
Alloca-
tion con-
cealment
Blinding
of partic-
ipants
and per-
sonnel
Blinding
of out-
come as-
sessment
Incom-
plete
outcome
data
Selective
report-
ing
Vested
interest
bias
Colchicine vs placebo
Olsson
1995
44 40 Unclear Unclear Low Low Unclear High Unclear High
Cyclosporin vs placebo
Sandborn
1993
16 10 Unclear Unclear Low Low High High High High
Infliximab vs placebo
Hommes
2008
4 3 Unclear Unclear Low Low High High High High
Methotrexate vs placebo
Knox
1994
11 10 Unclear Unclear Low Low High High High High
Ras-
mussen
1998
5 (crossed
over after
1 year)
8
(crossed
over after
1 year)
Unclear Unclear Unclear Unclear Unclear High Unclear High
NorUrsodeoxycholic acid vs placebo
Trauner
2016
Not
stated
Not
stated
Unclear Unclear Unclear Unclear Unclear High High High
Penicillamine vs placebo
90Pharmacological interventions for primary sclerosing cholangitis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Characteristics table (according to comparisons) (Continued)
LaRusso
1988
39 31 Unclear Unclear Low Low Unclear Low High High
Steroids vs placebo
Allison
1986
6 5 Unclear Low Low Low High High Low High
UDCA (high) vs placebo
Lindor
2009
76 74 Low Low Low Low Low High High High
UDCA (moderate) vs placebo
Bansi
1996
11 11 Unclear Unclear Unclear Unclear High High Unclear High
Mitchell
2001
13 13 Unclear Unclear Low Low Low High Unclear High
Olsson
2005
97 101 Unclear Low Low Low High Low High High
UDCA (low) vs placebo
Beuers
1992
6 8 Low Unclear Low Low Unclear High High High
Lindor
1997
51 51 Low Unclear Low Low High High High High
Lo 1992 7 7 Unclear Unclear Unclear Unclear High High Unclear High
Stiehl
1989
6 6 Unclear Unclear Unclear Unclear High High Unclear High
UDCA (low) vs UDCA (moderate) vs UDCA (high)
Cullen
2008
11 11
(UDCA
(moder-
ate)) and
9
(UDCA
(high))
Low Low Low Low High High High High
UDCA (low) vs colchicine vs placebo
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Table 1. Characteristics table (according to comparisons) (Continued)
De Maria
1996
20 19
(colchicine)
and 20
(placebo)
Unclear Unclear High Unclear Unclear High Unclear High
UDCA (low) plus metronidazole vs UDCA (low)
Farkkila
2004
37 34 Low Low Low Low High High High High
UDCA (low) plus mycophenolate vs UDCA (low)
Sterling
2004
6 10 Unclear Unclear High High Unclear High High High
Vancomycin vs metronidazole
Tabibian
2013
16 13 Unclear Unclear Low Low High High Low High
Vancomycin vs placebo
Rahim-
pour
2016
18 11 Low Low Low Low Low High Low High
A P P E N D I C E S
Appendix 1. Methods for network meta-analysis if we find this is possible in the future
Measures of treatment effect
Relative treatment effects
For dichotomous variables (e.g. proportion of participants with serious adverse events or any adverse events), we will calculate the odds
ratio with 95% credible interval (or Bayesian confidence interval) (Severini 1993). For continuous variables (e.g. quality of life reported
on the same scale), we will calculate the mean difference with 95% credible interval. We will use standardised mean difference values
with 95% credible interval for quality of life if included trials use different scales. For count outcomes (e.g. numbers of adverse events
and serious adverse events), we will calculate the rate ratio with 95% credible interval. For time-to-event data (e.g. mortality at maximal
follow-up), we will calculate hazard ratio with 95% credible interval.
Relative ranking
We will estimate ranking probabilities for all treatments of being at each possible rank for each intervention. Then, we will obtain the
surface under the cumulative ranking curve (SUCRA) (cumulative probability) and rankogram (Salanti 2011; Chaimani 2013).
Unit of analysis issues
We will collect data for all trial treatment groups that meet the inclusion criteria. The codes for analysis that we will use account for
the correlation between effect sizes from trials with more than two groups.
Assessment of heterogeneity
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We will assess clinical and methodological heterogeneity by carefully examining the characteristics and design of included trials. We
will assess the presence of clinical heterogeneity by comparing effect estimates under different categories of potential effect modifiers.
Different study designs and risk of bias may contribute to methodological heterogeneity.
We will assess the statistical heterogeneity by comparing results of the fixed-effect model meta-analysis and the random-effects model
meta-analysis, and between-study standard deviation (tau2 and comparing this with values reported in the study of the distribution
of between-study heterogeneity (Turner 2012)), and by calculating I2 (using Stata/SE 14.2). If we identify substantial heterogeneity -
clinical, methodological, or statistical - we will explore and address heterogeneity in a subgroup analysis (see ‘Subgroup analysis and
investigation of heterogeneity for network meta-analysis’ section).
Assessment of transitivity across treatment comparisons
We will evaluate the plausibility of the transitivity assumption (the assumption that participants included in different studies with
different immunosuppressive regimens can be considered part of a multi-arm randomised clinical trial and could potentially have been
randomised to any treatment) (Salanti 2012). In other words, any participant who meets the inclusion criteria is, in principle, equally
likely to be randomised to any of the above eligible interventions. If we have any concern that clinical safety and effectiveness are
dependent upon effect modifiers, we will continue to do traditional Cochrane pair-wise comparisons and will not perform a network
meta-analysis on all participant subgroups.
Assessment of reporting biases
For the network meta-analysis, we will judge reporting bias by completeness of the search (i.e. searching various databases and including
conference abstracts), as we do not currently find any meaningful order to performing a comparison-adjusted funnel plot, as suggested
by Chaimani 2012. However, if we find any meaningful order, for example, the control group used depended upon the year of conduct
of the trial, we will use a comparison-adjusted funnel plot, as suggested by Chaimani 2012.
Data synthesis
Methods for indirect and mixed comparisons
We will conduct network meta-analyses to compare multiple interventions simultaneously for each of the primary and secondary
outcomes. Network meta-analysis combines direct evidence within trials and indirect evidence across trials (Mills 2012).We will obtain
a network plot to ensure that trials were connected by treatments using Stata/SE 14.2 (Chaimani 2013). The network plot for mortality
at maximal follow-up for this review is presented in Figure 5. We will exclude any trials that were not connected to the network. We will
conduct a Bayesian network meta-analysis using the Markov chain Monte Carlo method in OpenBUGS 3.2.3, as per guidance from
the National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) documents (Dias 2014a). We will model
treatment contrast (i.e. log odds ratio for binary outcomes, mean difference or standardised mean difference for continuous outcomes,
log rate ratio for count outcomes, and log hazard ratio for time-to-event outcomes) for any two interventions (’functional parameters’)
as a function of comparisons between each individual intervention and an arbitrarily selected reference group (’basic parameters’) (Lu
2006) using appropriate likelihood functions and links. We will use binomial likelihood and logit link for binary outcomes, Poisson
likelihood and log link for count outcomes, binomial likelihood and complementary log-log link for time-to-event outcomes, and
normal likelihood and identity link for continuous outcomes. We will apply a fixed-effect model and a random-effects model for the
network meta-analysis. We will report both models for comparison with the reference group in a forest plot. For pair-wise comparison,
we will report the fixed-effect model if the two models reported similar results; otherwise, we will report the more conservative model.
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Figure 5. Network plot for mortality at maximal follow-up. The size of the node (circle) provides a measure
of the number of trials in which the particular treatment was included in one of the arms. The thickness of the
line provides a measure of the number of direct comparisons between two nodes (treatments).
We will use a hierarchical Bayesian model using three different initial values and codes provided by NICE DSU (Dias 2014a). We will
use a normal distribution with large variance (10,000) for treatment effect priors (vague or flat priors). For the random-effects model,
we will use a prior distributed uniformly (limits: 0 to 5) for between-trial standard deviation but assumed similar between-trial standard
deviation across treatment comparisons (Dias 2014a). We will use a ’burn-in’ of 5000 simulations, check for convergence visually, and
run models for another 10,000 simulations to obtain effect estimates. If we did not obtain convergence, we will increase the number
of simulations for ’burn-in’. If we do not obtain convergence still, we will use alternate initial values and priors according to methods
suggested by van Valkenhoef 2012. We will also estimate the probability that each intervention ranks at one of the possible positions
using the NICE DSU codes (Dias 2014a).
Assessment of inconsistency
We will assess inconsistency (statistical evidence of violation of the transitivity assumption) by fitting both an inconsistency model and
a consistency model. We will use inconsistency models described in the NICE DSU manual, as we plan to use a common between-
study deviation for comparisons (Dias 2014b). In addition, we will use the design-by-treatment full interaction model (Higgins 2012)
and IF (inconsistency factor) plots (Chaimani 2013) to assess inconsistency. In the presence of inconsistency, we will assess whether it
is due to clinical or methodological heterogeneity by performing separate analyses for each of the different subgroups mentioned in the
‘Subgroup analysis and investigation of heterogeneity for network meta-analysis’ section below.
If we find evidence of inconsistency, we will identify areas in the network where substantial inconsistency might be present in terms
of clinical and methodological diversities between trials and, when appropriate, will limit network meta-analysis to a more compatible
subset of trials.
Direct comparison
We will perform direct comparisons using the same codes and the same technical details.
Sample size calculations
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To control for risk of random errors, we will interpret information with caution when the accrued sample size in the network meta-
analysis (i.e. across all treatment comparisons) was less than the required sample size (required information size). For calculation of the
required information size, see Appendix 3.
Subgroup analysis and investigation of heterogeneity for network meta-analysis
We will assess differences in effect estimates between subgroups listed in subgroup analysis and investigation of heterogeneity using
meta-regression with the help of the OpenBUGS code (Dias 2012a) if we include a sufficient number of trials. We will use potential
modifiers as study level co-variates for meta-regression. We will calculate a single common interaction term (Dias 2012a). If 95%
credible intervals of the interaction term do not overlap zero, we will consider this as evidence of difference in subgroups.
Presentation of results
We will present effect estimates with 95% CrI for each pair-wise comparison calculated from direct comparisons and network meta-
analysis. We will present the cumulative probability of treatment ranks (i.e. the probability that the treatment is within the top two,
the probability that the treatment is within the top three, etc.) in graphs (surface under the cumulative ranking curve, or SUCRA)
(Salanti 2011). We will plot the probability that each treatment is best, second best, third best, etc., for each of the different outcomes
(rankograms), which generally are considered more informative (Salanti 2011; Dias 2012b).
We will present ’Summary of findings’ tables for mortality. In Summary of findings for themain comparison, wewill follow the approach
suggested by Puhan et al. (Puhan 2014). First, we will calculate direct and indirect effect estimates and 95% credible intervals using
the node-splitting approach (Dias 2010) (i.e. calculate the direct estimate for each comparison by including only trials that performed
direct comparisons of treatments, and the indirect estimate for each comparison by excluding trials that performed direct comparisons
of treatments). Then we will rate the quality of direct and indirect effect estimates using GRADE, which takes into account risk of
bias, inconsistency, directness of evidence, imprecision, and publication bias (Guyatt 2011). We will present estimates of the network
meta-analysis and will rate the quality of network meta-analysis effect estimates as the best quality of evidence between direct and
indirect estimates (Puhan 2014). In addition, in the same table, we will present illustrations and information on numbers of trials and
participants, as per the standard ’Summary of findings’ table.
Appendix 2. Search strategies
Database Time span Search strategy
Central Register of Controlled Trials
(CENTRAL) (Wiley).
Issue 2, 2017. #1 MeSH descriptor: [Cholangitis, Sclerosing] ex-
plode all trees
#2 primary sclerosing cholangitis or PSC
#3 #1 or #2
MEDLINE (OvidSP). January 1947 to February 2017. 1. exp Cholangitis, Sclerosing/
2. (primary sclerosing cholangitis or PSC).mp. [mp=
title, abstract, original title, name of substance word,
subject heading word, keyword heading word, pro-
tocol supplementary concept word, rare disease sup-
plementary concept word, unique identifier]
3. 1 or 2
4. randomised controlled trial.pt.
5. controlled clinical trial.pt.
6. randomised.ab.
7. placebo.ab.
8. drug therapy.fs.
9. randomly.ab.
10. trial.ab.
11. groups.ab.
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(Continued)
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. exp animals/ not humans.sh.
14. 12 not 13
15. 3 and 14
Embase (OvidSP). January 1974 to February 2017. 1. exp primary sclerosing cholangitis/
2. (primary sclerosing cholangitis or PSC).mp. [mp=
title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
3. 1 or 2
4. exp crossover-procedure/ or exp double-blind pro-
cedure/ or exp randomised controlled trial/ or single-
blind procedure/
5. (((((random* or factorial* or crossover* or cross
over* or cross-over* or placebo* or double*) adj
blind*) or single*) adj blind*) or assign* or allocat*
or volunteer*).af
6. 4 or 5
7. 3 and 6
Science Citation Index - Expanded (Web
of Knowledge)
January 1945 to February 2017. #1 TS=(primary sclerosing cholangitis or PSC)
#2 TS=(random* OR rct* OR crossover ORmasked
OR blind* OR placebo* OR meta-analysis OR sys-
tematic review* OR meta-analys*)
#3 #1 AND #2
World Health Organization International
Clini-
cal Trials Registry Platform Search Portal (
apps.who.int/trialsearch/Default.aspx)
February 2017. Condition: primary sclerosing cholangitis
ClinicalTrials.gov February 2017. Interventional Studies | primary sclerosing cholangi-
tis | Phase 2, 3, 4
Appendix 3. Sample size calculation
Five-year mortality in patients with primary sclerosing cholangitis is 18% (Talwalkar 2001). The required information size is based
on a control group proportion of 18%, a relative risk reduction of 20% in the experimental group, type I error of 5%, and type II
error of 20% in 3396 participants. Network analyses may be more prone to risk of random error than direct comparisons (Del Re
2013). Accordingly, a larger sample size is required in indirect comparisons than in direct comparisons (Thorlund 2012). Power and
precision in indirect comparisons depend upon various factors, such as the number of participants included under each comparison and
heterogeneity between the trials (Thorlund 2012). If no heterogeneity is evident across trials, the sample size in indirect comparisons
would be equivalent to the sample size in direct comparisons. The effective indirect sample size can be calculated using the number
of participants included in each direct comparison (Thorlund 2012). For example, a sample size of 2500 participants in the direct
comparison A versus C (nAC) and a sample size of 7500 participants in the direct comparison B versus C (nBC ) result in an effective
indirect sample size of 1876 participants. However, in the presence of heterogeneity within comparisons, the sample size required is
greater. In the above scenario, for an I2 statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2) of 25%, the
effective indirect sample size is 1407 participants. For an I2 statistic for each of the comparisons A versus C and B versus C of 50%,
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the effective indirect sample size is 938 participants (Thorlund 2012). If the study includes only three groups and sample size is greater
than required information size, we will calculate the effective indirect sample size using the following generic formula (Thorlund 2012):
((nAC × (1 - IAC
2)) × (nBC × (1 - IBC
2))/((nAC × (1 - IAC
2)) + (nBC × (1 - IBC
2)).
Nomethod is currently known to calculate the effective indirect sample size for a network analysis involvingmore than three intervention
groups.
WH A T ’ S N E W
Date Event Description
12 April 2017 Amended TheCochraneCentral Editorial Unit requested removal of the ’attempted networkmeta-analysis’ phrase
from the end of the review title, as this further description of the review might create confusion in the
reader. Although we followed the planned methodology for network meta-analysis, it was not possible
to assess whether the potential effect modifiers were similar across different comparisons. Therefore, we
did not perform the network meta-analysis and instead assessed the comparative benefits and harms of
different interventions using standard Cochrane methodology
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. It was not possible to assess whether potential effect modifiers were similar across different comparisons. Therefore, we did not
perform the network meta-analysis but instead assessed comparative benefits and harms of different interventions using standard
Cochrane methods. The method that we plan to use if we conduct a network meta-analysis in the future is available in Appendix 1.
2. We performed Trial Sequential Analysis in addition to conventional methods of assessing risk of random errors using the P value.
N O T E S
We have noted considerable overlap between the Methods of this review and those of several other protocols and reviews written by
the same group of review authors.
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